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Abstract of the dissertation
Human Immunodeficiency Virus Type 1 Envelope Protein Interaction with
Host Cell Coreceptor C-X-C Chemokine Receptor Type 4
by
Jie Zhang
Doctor of Philosophy in Biology and Biomedical Sciences
Immunology
Washington University in St. Louis, 2015
Professor Lee Ratner, Chair

Human Immunodeficiency Virus Type 1 (HIV-1) envelope protein is the sole
determinant for viral entry and tropism. The ability of HIV-1 to infect susceptible host cells
depends on the ability of its envelope protein to engage host cell receptor CD4 and coreceptor CC Chemokine Receptor Type 5 (CCR5) and/or C-X-C Chemokine Receptor Type 4 (CXCR4).
Most naturally occurring infections start with a single CCR5-tropic virion. In approximately 50%
of HIV-1 Clade B infected patients, the viral population spontaneous develops the ability to
utilize CXCR4 at a late disease stage, and this coreceptor shift corresponds to a poor prognosis
for the patients. Clinical application of a CCR5 antagonist drug accelerates this coreceptor shift
process. Despite the important implications of HIV-1 tropism on disease pathogenesis,
prognosis, and treatment, molecular mechanisms for coreceptor shift and the contributing
envelope determinants have not yet been clearly defined due to the dynamic, multimeric, multistep nature of envelope-coreceptor interaction. In order to better understand the regions on
envelope that are important for coreceptor specificity, we studied a panel of HIV-1 envelope
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amplicon samples from patients who experienced coreceptor shift and treatment failure in a
CCR5 antagonist clinical trial. In order to further understand the structure-function relationship
of HIV-1 envelope, we utilized both in-depth single clone analysis to fully characterize the
functional attributes of individual envelope isolates, and high-throughput deep sequencing
analysis to investigate the global envelope variant landscape before and after treatment.
In the single clone analysis, we applied both tissue-culture based phenotypic tropism
characterization, as well as sequence-based genotypic analysis towards 97 single envelope clones
isolated from four samples of two study subjects. Unique quasispecies composition were found
post coreceptor shift in two individuals who had different courses of disease. In addition, one
subject showed drastic sequence variation between isolates from before and after treatment, and
a highly homogeneous viral population post treatment. This suggested a rapid shift to CXCR4using variants that accounted for failure to respond to CCR5 antagonist treatment.
In the deep sequencing analysis, we developed a novel comprehensive approach to
sequence a large number of phenotypic validated variants on two next-generation sequencing
platforms. This approach offered an unprecedented view of the viral quasispecies landscape in
vivo, as well as on the dynamic population change in response to drug selection. Regions of
interest that strongly associated with the usage of CXCR4 coreceptor were identified, including
previously reported coreceptor specificity sites within and outside V3, the CD4 binding site, and
gp41-gp120 interaction site within the same protomer and between neighboring protomers in the
envelope trimer spike. These findings have potentially implications in rational design of better
coreceptor inhibitors, and development of more accurate predictive algorithms for HIV-1
envelope tropism.
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Chapter 1
Introduction

1

Human Immunodeficiency Virus (HIV) is an enveloped virus that enters into a
susceptible host cell via a receptor-mediated fusion event between the host cell membrane and
viral membrane (1-3). Like most enveloped viruses, this receptor binding process is mediated by
a viral glycoprotein located on the lipid envelope of the virus, such as the envelope protein on
HIV and the hemagglutinin protein on influenza virus (4, 5). The specificity of viral protein and
host cell receptor interaction determines the range of host cell types that a virus could potentially
infect, namely the viral tropism. Viral tropism is critical in disease pathogenesis and progression,
prognosis, and treatment options. In this chapter, I will introduce some background knowledge
on HIV virology and pathogenesis, envelope structure and cell entry process, tropism shift and
its potential therapeutic implications, as well as the current and future tropism testing approaches.

2

1.1 HIV-1 and AIDS
HIV is a complex retrovirus and the etiologic agent of acquired immunodeficiency
syndrome (AIDS) first discovered in 1983. A virion comprises of a nucleocapsid core, where its
genetic information is stored in two copies of its positive sense single stranded RNA genome,
and encapsulated by viral matrix proteins and nucleocapsid protein. On the exterior of the
nucleocapsid core there is a roughly spherical-shaped lipid bilayer membrane called the envelope
(6). On the lipid bilayer membrane, there are viral envelope proteins forming trimeric spikes that
can interact with the host cell surface receptor and coreceptors to initiate an infection (7).
HIV/AIDS remains a major global public health problem today. About 37 million people
world-wide are living with HIV infection as of the end of 2014. Over 34 million deaths have
occurred to-date as a result of HIV infection. Each year there are 2 million new infection cases
and approximately 1.2 million HIV-associated deaths. The pandemic is the most severe in
regions of sub-Saharan Africa where there is heavy disease burden and poor access to testing and
treatment (Figure 1.1) (UNAIDS) (8).
The term HIV refers to two distantly related viruses, HIV-1 and HIV-2, which were
independently introduced from their zoonotic origins to humans (9, 10). HIV-1 is more
pathogenic and responsible the global AIDS epidemic, whereas HIV-2 is less infectious, with
cases mostly restricted to West African regions, and has a slower progression to full-blown
AIDS. HIV-1 can be further categorized into Groups including M, N, O, and P, of which Group
M (main) causes the majority of HIV-1 infection world-wide. Based on sequence diversity,
Group M is further classified in subtypes A, B, C, D, F, G, H, J, K, and circulating recombinant
forms (CRFs) (11, 12). The dominant subtype in the Americas and Europe is Subtype B, while
over half of all HIV cases are caused by Subtype C, which is also the most dominant subtype in
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Africa. The different subtypes represent rapid evolution of HIV-1 in various geographic areas as
a direct consequence of its high mutation and recombination rate as well as its high turnover rate
in the host.
The current standard of care for HIV patients is typically a combination of antiretroviral
drugs in a treatment called highly active antiretroviral therapy (HAART) (13). HAART drugs
target primarily three viral proteins, protease, reverse transcriptase, and integrase. Current WHO
recommendation on first time baseline combination includes two nucleoside reverse transcriptase
inhibitors (NRTI) and one non-nucleoside reverse transcriptase inhibitor (NNRTI), one protease
inhibitor (PI) or one integrase inhibitor (WHO) (14, 15). HAART can effectively suppress
circulating viral load, therefore, significantly reducing mobility and mortality of AIDS, but it
does not provide a cure (16, 17). A drug holiday for one or two weeks can result in a blood viral
load rebound back to the pre-treatment level (18). Therefore, the treatment has to be taken
continuously for life. Apart from the public health issues that accessibility to HAART drugs are
far from universal, taking antiretroviral drugs long term could lead to other complications
including toxicity and development of drug-resistant strains of HIV (19-21). Taken together, the
present treatment options for HIV/AIDS are insufficient to address the global AIDS pandemic,
and more efforts are needed to understand the biology of HIV infection in the hope to provide
guidelines in future drug and vaccine development processes.

4

1.2 HIV life cycle and pathogenesis
A productive HIV-1 infection at the cellular level starts with viral entry (Figure 1.2) (1,
6). Following attachment to the extracellular matrix or cell surface receptors of a susceptible cell,
the viral envelop protein engages with a cell surface receptor CD4, undergoes a large
conformational change, and then engages with its coreceptor, CCR5 or CXCR4 (22, 23). Upon
coreceptor binding, further conformational changes occur, inserting the fusion peptide into the
cellular membrane, pulling together the viral membrane and the cellular membrane to a critical
distance, resulting in hemi-fusion and fusion of the two membranes. After the formation of
fusion pore, the virion nucleocapsid is transported into the cytoplasm of the infected cells.
Once the HIV nucleocapsid core enters the cytoplasm, uncoating occurs and converts the
nucleoprotein core into the reverse transcription complex (RTC) (24) where reverse transcription
of the viral RNA genome into a double-stranded DNA copy takes place (25, 26). The RTC is
then transformed into the pre-integration complex (PIC), chaperoned to the nuclear pore where
the PIC enters the nucleus for integration. Upon integration, the viral DNA genome becomes part
of the chromosomal DNA in the infected cell and is called a provirus. Expression of viral RNA
and proteins are realized through cellular transcription and translation machineries. Newly
manufactured viral constituents are transported to the plasma membrane of the infected cell,
where viral assembly and budding occur. The gag-pro-pol polyprotein mediates the assembly
process by packaging two copies of positive sense single-strand viral genomic RNA into the
budding virion, recruiting accessory proteins and envelope protein, and generating a spherical
viral particle. The host endosomal sorting complexes required for transport (ESCRT) system
releases the particles from the plasma membrane of the infected cells (27). Upon budding, the
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viral protease cleaves the Gag-Pol polyprotein, resulting in fully processed structural components
that rearrange to form a mature nucleocapsid core capable of infecting a new host cell (6, 28, 29).
At an organismal level, HIV can be transmitted through sexual, percutaneous, and
perinatal routes. A new infection via mucosal transmission is typically established by a single
CCR5-tropic founder virus that infects a partially activated memory CD4+ T lymphocyte near the
site of exposure (30). The infected T cell then migrates to a draining lymph node to start a
peripheral infection, which then quickly proceeds to a systemic infection within weeks. During
the initial stages of infection, CD4+ T cells in gut-associated lymphoid tissues (GALT) are
massively depleted due to active infection as well as abortive infection induced through bystander T cell pyroptosis (31). Cellular, and later, humoral immune responses counteract active
viral replication and infection but are unable to clear the virus, resulting in a viral load set-point
that usually is stable throughout the seven to ten years of the clinical latency period. In the later
phase of infection, especially by the time immunodeficiency starts, the virus has largely depleted
CCR5-expressing memory T cell compartment, and sometimes evolved to infect CXCR4expressing naïve T cells. HIV/AIDS patients, if untreated, usually become so
immunocompromised that they succumb to multiple severe opportunistic infections that are rare
and non-life-threatening in immunocompetent individuals (32, 33).
A thorough understanding of the HIV viral life cycle and its disease pathogenesis is
central to the development of intervening methods that block the replication cycle or stop disease
progression. For example, entry inhibitors prevent the virus from infecting a target cell in the
first place, thus, such agents could potentially be used in pre-exposure microbiocide creams or as
post-exposure prophylactics (34). Entry inhibitors also prevent the newly released virus from
undergo another round of infection, thus, they could be used as one component of the HAART
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regimen cocktail in combination with other drugs to suppress viral replication in a chronically
infected patient.

7

1.3 HIV-1 cell entry and entry inhibitors
Viral entry into a susceptible target cell is the first step in the virus replication cycle. The
entry event might occur at the plasma membrane or within an endocytic compartment of a
targeted cell in a pH-independent manner (1). Viral entry, mediated by the envelope protein, is a
dynamic, multimeric, multi-step process that involves several protein-protein interactions,
consecutive conformational changes, membrane fusion, and the eventual translocation of the
viral nucleocapsid core (Figure 1.3) (28). Several key steps in the entry process are being
targeted for the development of entry inhibitors (35-40).
During viral attachment, nonspecific interactions with the extracellular heparan sulfate
proteoglycans, and specific interaction with cell surface proteins DC-SIGN and α4β7 integrin,
bring the virion to a close proximity with the plasma membrane of a target cell. The viral
envelope trimeric spike encounters and engages CD4, the primary host receptor required for
HIV-1 infection (41-43). CD4 is an immune cell surface marker expressed on a subset of T
lymphocytes (CD4+ T cells), dendritic cells (CD4+ DCs), and macrophages, all of which are cell
types susceptible to HIV-1 infection. CD4 binding to gp120 leads to a conformational change
that forms a bridging sheet, and allows an otherwise buried region including variable loop (V3)
to be repositioned and exposed, forming a critical contact platform for the subsequent coreceptor
interaction step (44).
Human chemokine receptors, CCR5 and CXCR4, are the two major coreceptors playing
significant roles in viral entry in vivo. Both CCR5 and CXCR4 are G-protein coupled seventransmembrane receptors that are expressed on a variety of cell types including certain immune
cell subsets. In a normal immunological context, interaction between chemoattractant cytokines
and their receptors interact and modulate immune cell migration and sometimes influx into sites
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of injury and inflammation. CXCR4 is widely and constitutively expressed on many cell types,
including thymocytes and naïve T cells that require CXCR4-CXCL12 interaction for
development and homeostasis (45). In a pathological context, CXCR4 also plays an important
role in cancer cell survival and metastasis. On the other hand, CCR5 has a narrower expression
profile including activated and memory T cells. CCR5 interacts with its ligands MIP1, MIP1
and RANTES for T cell costimulation and inflammatory immune responses, though it appears to
be dispensable, with no severe immunodeficiency in people carrying homozygous null alleles
(46).
The process of envelope-coreceptor interaction is not clearly defined but is thought to
occur according to a two-site model. Site one is the amino-terminus of a coreceptor that interacts
with the base of V3 loop, and site two is the extracellular loops of a coreceptor that interacts with
the now exposed V3 region on gp120 upon CD4 binding (47, 48). As the coreceptors fully
engage gp120, further conformational changes allow the hydrophobic gp41 fusion peptide to
inserts into the host membrane, while the transmembrane domain of gp41 still anchors its
carboxyl terminus in the viral membrane. As a Class I fusion machinery, two heptad repeat (HR)
regions in gp41, HR1 and HR2, fall back on each other in antiparallel orientation, forming a
coiled-coil six-helical bundle that pulls together the viral and host membrane to a proximity close
enough for mixing of the outer leaflet of the two membranes, and eventual formation of a fusion
pore (49-52). The viral nucleocapsid is then translocated through the pore into the host cell
cytoplasm.
A number of therapeutic developments focus on blocking different steps in the entry
process, such as CD4 binding, coreceptor binding, and fusion (34, 53, 54). For example, vaccine
engineering research focuses on broadly neutralizing antibodies that target native envelope
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trimers in an attempt to block viral attachment or entry (55-60). Small molecules and monoclonal
antibodies are tested for their ability to target CD4 or the CD4 binding site on gp120 (61-63).
Fusion inhibitors include Enfuvertide (Fuzeon, Roche), which is a 36-amino-acid-long HR2based peptide that competes with HR2 and binds to HR1 in gp41 region , therefore preventing
the formation of the six-helical bundle and stopping fusion (64-70). With the discovery of a rare,
naturally occurring, protective loss-of-function CCR532 mutation, blocking or removing CCR5
from the host cell became an attractive strategy (71, 72). Small molecule antagonists and gene
therapy agents such as Zinc finger nucleases (ZFN) have been studied in the laboratories and in
clinical trials (73-78). Maraviroc (MRV), a small molecular CCR5 antagonist, is the only
coreceptor inhibitor approved by Food and Drug Administration (FDA) as a second line
treatment for patients who have exhausted first line options (48, 79-83). Inhibitors to CXCR4
were developed but not approved for long-term HIV treatment due to its adverse effects. Single
dose administration of AMD3100 (Mozobil or Plerixafor), a potent CXCR4 inhibitor, is
approved to be used in bone marrow donors to mobilize bone-marrow residing hematopoietic
stem cells before transplant but is not used for HIV-1 treatment due to side effects (84, 85).
Overall, HIV-1 viral entry is a multi-step process that remains an attractive target for
active development of entry inhibitors (86-88). Although a number of small molecule drugs and
biologics are being studied in clinical trials, only two were FDA approved to be used as second
line HIV drugs. More effort to understand the molecular details between HIV-1 envelope and
coreceptor interaction during cell entry can provide valuable guideline for the future
development of efficacious, precisely-targeting therapeutic agents.
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1.4 Envelope structure and tropism determinants
The native HIV-1 envelope protein exists as a trimer of gp120-gp41 heterodimers on the
viral membrane. The full-length envelope precursor protein gp160 is cleaved into a
transmembrane subunit called gp41 and a surface subunit called gp120 (89). The two subunits
are non-covalently attached, and form a trimer of heterodimers on the viral lipid membrane,
called an envelope trimer spike (90). Based on structural studies and models, one HIV-1 virion
has approximately 14 envelope spikes, on average, on its lipid membrane, which is a very low
number compared to other enveloped viruses, such as influenza and dengue viruses (7, 91). The
sparse location of envelope spikes on a virion is thought to minimize crosslinking of B cell
receptor and elicitation of a humoral immune response (92). In addition, gp120 is heavily
glycosylated with over 20 glycosylation sites (93). The glycan shield on the exterior of the
envelope spike also helps to evade the neutralizing antibody response (94, 95).
HIV-1 gp120 can be further divided into five relatively conserved regions (C1 through
C5) that form the gp120 core, interspersed by five variable regions (V1 through V5) that are
mostly located at or near the outer surface of gp120 to shield the more conserved inner core from
the immune system (Figure 1.4) (96-99). Disulfide bridges link the two cysteine residues at the
base of each variable loop except for V5. The variable loops are named due to their sequence
hyper-variability among different envelope isolates. Among the five variable loops, the V3 loop
is much less variable than V1/2 and V4, especially in terms of insertions and deletions (44).
The V3 loop has been extensively studied for its critical role in coreceptor binding
(Figure 1.5) (96). Sub-regions in V3 have been shown to be conserved, especially in CCR5-using
viruses (R5 viruses), highlighting the possibility that V3 interacts directly with CCR5 with some
degree of structural stringency. On the other hand, the V3 sequences in CXCR4-using viruses
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(X4 viruses) are more diverse. Currently, a plethora of mutagenesis and structural studies support
the theory of a CCR5 amino-terminal interaction with the base of V3, in particular a sulphated
tyrosine at Position 10 of CCR5 forming a salt bridge interaction with a highly conserved
arginine at Position 327 of gp120. Computational docking simulations also demonstrated a
possible interaction between the CCR5 amino-terminus with the CD4-bound gp120 structure.
However, there is no direct crystallographic evidence or molecular details of the direct
interaction between the V3 loop and CCR5 or CXCR4 extracellular domains.
Besides being a critical piece in coreceptor binding, the V3 loop is also the principal
determinant in coreceptor specificity (100, 101). The functional capacity of gp120 to interact
with CCR5 and/or CXCR4 bears clinical significance in treatment options and disease prognosis.
Studies show that in an artificial pseudotyping system, exchanging the V3 loops between CCR5tropic and CXCR4-tropic envelope strains can result in a switch in tropism, demonstrating the
importance of V3 in coreceptor choice (102). However, in vivo envelope mutation and evolution
in a physiological context is more complex. For example, the 11/25 Rule states that positively
charged residues on the V3 loop in particular at Position 11 and 25, as well as the net positive
charge of V3, are strongly associated with CXCR4 usage.
A large body of literature has focused on the V3 loop, as it is the principal determinant of
HIV-1 tropism (103-107). However, HIV-1 envelop also modulates its interaction with the
coreceptor via regions outside the V3 loop (108-112). Covariance of a negatively charged amino
acid at Position 440 in C4 region and a positively charged residue at Position 322 in V3 were
shown to associate with strong with R5-using Subtype B virus; incorporating the status of
Position 440 could improve the predictive power of existing tropism predictive algorithms.
Mutations in gp41 correlate highly with X4-usage and are validated in patients in MRV clinical
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trials (113). Biochemical and biophysical analysis also showed that residues that influence
tropism are identified in V1, V2, C4, and gp41 regions (114). In particular, the tropismdetermining residues of gp41 likely influence gp120-coreceptor interaction via modulating
binding affinity and complex stability (115). Since the envelope-coreceptor interaction is a
multimeric, highly dynamic process, residues that are not located at the contact surface might
still influence the tropism indirectly by stabilizing or destabilizing the interaction with a
coreceptor (116). A more thorough and nuanced understanding of gp120-gp41-CD4-coreceptor
interaction, including the role of V3 and determinants outside V3, would potentially improve
tropism predictive algorithms and reveal new drug targets (117).
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1.5 HIV-1 quasispecies and coreceptor shift
HIV-1 exists in patients not as a homogenous clone of virus with identical genomes, but
as a quasispecies, or a group of related but non-identical variants. This population of variants is a
result of high levels of viral replication soon after the initial infection (118). As previously
mentioned, a new infection usually starts from a single R5-tropic transmitter / founder virus.
Upon establishment of a productive infection, rapid replication occurs, with mutations and
recombination accumulating, and selected along the way for improved fitness in the host. The
error-prone viral reverse transcriptase, in combination with rapid viral reproduction, results in an
estimated mutation rate that allows changes at every single nucleotide position in the viral
genome within a day (119-122). Therefore, a viral quasispecies population in the host is
adaptable to various selection pressures coming from the host immune system or from
antiretroviral therapies (123). The HAART regimen was developed based on this understanding,
that the virus can quickly become resistant to any mono-therapy, but it is less likely to gain
resistance to multiple drugs administered simultaneously.
In the context of tropism, at the early stage of HIV-1 infection, CCR5-tropic virus
predominates largely over the asymptomatic period, probably reflecting a bottleneck event in the
transmission process. As the CCR5-expressing T cells are depleted, selection pressure drives the
quasispecies to utilize the alternative coreceptor CXCR4 and in the presence of less CD4
expression. Current nomenclature broadly categorizes HIV-1 isolates into CCR5-tropic (R5),
CXCR4-tropic (X4), and CCR5/CXCR4-tropic (dual or R5X4) clones. In reality, however,
strictly R5-tropism and strictly X4-tropism are the opposite ends of a spectrum, where most
physiological variants fall on the spectrum in between the two ends. Strictly X4-tropic variants
are rare, as most infections start with a R5-tropic virus and evolve towards different levels of
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capacity in using CXCR4. Approximately 50% of HIV-1 Clade B patients spontaneously
develop X4-using viruses in the later stage of infection, and the presence of X4-using virus
(including dual-tropic and X4-tropic) correlates with a worse clinical prognosis (124). It is
unclear whether the emergence of X4-using virus is the cause or result of a more severe disease.
Some patients receiving CCR5 antagonist therapy experience an expedited course of X4using virus emergence and become unresponsive to the coreceptor inhibitor treatment (Figure
1.6). This could lead to treatment failure and viral load rebound. The conversion from R5tropism to dual- or X4-tropism is called coreceptor shift. Again it is unclear if this presence of
X4-using virus will cause worse disease outcome, or whether it is the result of disease
progression. In some of the individuals who undergo coreceptor shift, the viral tropism reverts
back to R5 upon withdrawal of the CCR5 antagonist therapy, reflecting the adaptability of the
quasispecies population in response to external selection pressures, as well as a potential fitness
cost in X4-usage (125).
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1.6 Phenotypic tropism testing
The current gold standard for viral tropism determination is tissue-culture based
phenotypic tests, such as the Enhanced Sensitivity Trofile Assay (ESTA) (126-128). The
phenotypic testing is usually performed by pseudotyping patient-derived gp160 coding sequence
on infectious particles, and infecting cell lines expressing CD4 and CCR5 or CXCR4 using these
pseudotyped viruses. The infection outcome is detected with a reporter system such as
fluorescence or luminescence. The advantage of a phenotypically based assay is that it is highly
accurate, sensitive, and includes all tropism determinants on the full-length gp160 envelope
region. The ESTA reports 100% sensitivity at detecting 0.3% X4-using minor variant at a
starting viral load larger than or equal to 1000 copies per milliliter of blood. The disadvantages
of a phenotypic assay include high cost, long turn-around time, sometimes inconclusive results,
and being labor-intensive. Since clinical administration of a CCR5 antagonist requires prior
tropism determination that the patient does not harbor X4-using variants, such drawbacks of the
phenotypic tropism testing directly limit the application of the CCR5 antagonist drug.
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1.7 Genotypic tropism testing
With the impressive advancement of the next-generation-sequencing (NGS) technology
over the past decade, genotypic analysis of HIV-1 quasispecies becomes feasible (129-136).
NGS technology was developed to meet the demand for higher-throughput, cheaper sequencing
methods in the Human Genome Project, and has become increasingly useful in the study of
microbial communities called the microbiome. The ability to produce sequencing libraries in a
cell-free system without cloning, the massive parallelization of sequencing reactions from the
advancement of microfluidics technology, and the real-time base-interrogation technology
without the need for electrophoresis, allow millions and billions of sequencing reads to be
produced in one run (137). The unprecedented scale and speed of NGS opened doors for
genomic and genotypic approaches in disease diagnosis and testing, including HIV-1 tropism
testing.
Illumina sequencing technology is the most widely used mainstream NGS platform today.
It has different sequencing systems developed for different applications based on genome size
and output volume. The MiSeq system is designed to sequence small genomes, amplicons or
targeted gene panels with a fast turnaround time (within 6 hours), ideal for genotypic
determination in clinical laboratories (138). The basic workflow of Illumina NGS system
includes fragmentation of input DNA into several hundred base-pairs, ligation of an adaptor on
both ends of the fragments, immobilization of the adaptor-DNA fragment on a flow cell, solidphage bridge amplification to produce millions of densely packed clusters, and sequencing by
synthesis using labelled nucleotide terminators (Figure 1.7). Each cluster comes from one DNA
fragment in the input sample, and will produce one read after sequencing. A CCD camera is used
to capture fluorescence as each terminator base is being added to the growing DNA polymer, and
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the output reads are typically 50 – 250 nucleotides in length, depending on the sequencer and
customized settings. The advantage of Illumina sequencing lies in its massive amount of output,
ranging from millions to billions of reads per run. This allows hundreds to tens of thousands
folds of coverage for a small genome or an amplicon gene. It is ideal to uncover rare variants that
comprises of less than 1% of the input population, for example in a patient-derived HIV-1
envelope amplicon sample where the majority of the variants are R5-tropic but minor X4-tropic
variants exist at a low percentage (139-142). The challenge for genotypic testing by Illumina
sequencing comes from the need to reconstruct short reads into a longer haplotype. It is difficult
to analyze mutations that are longer than the length of the reads, as the linkage information
would be lost over the fragmentation and sequencing process.
In order to address the issues brought about by the short read length in Illumina
technology, several new cutting-edge “third-generation sequencing” technologies that focuses on
longer sequence of single DNA molecules emerged. I will still call them next-generation
sequencing for the sake of simplicity. Pacific Biosciences (PB) single-molecule, real-time
(SMRT) sequencing is one of them (Figure 1.8) (143, 144). Some breakthroughs for the PB
sequencing technology include (1) utilization of zero-mode waveguides that are small wells on a
SMRT cell to house single DNA molecule, therefore blocking light from other sequencing
reactions and reduce background noise; a novel DNA polymerase and sequencing chemistry that
can generate long reads up to tens of kilobases in length; and (3) sequencing in a circular fashion
to allow multiple passes on the input DNA fragment on both strands, therefore resulting in a
circular consensus sequence (CCS) for each single molecule sequenced and reducing error rate.
Comparing to Illumina platforms, PB sequencing generates fewer reads in the range of thousands
to tens of thousands, therefore the coverage is not as high but still more than sufficient in
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analysis of a small genome or amplicon. In the context of genotypic testing for HIV-1 tropism,
the added advantage of PB sequencing is that mutation located at different domains of the
envelope gene can be correlated thanks to the long CCS reads. It affords analysis of covariance
between different loci and allows better understanding of structure-function relationship of the
envelope.
Since the NGS-based genotypic assays routinely multiplex samples to maximize the
utilization of its massive sequencing capacity, development of high-throughput low-cost
genotypic testing methods is a possibility. With a deep coverage and robust analysis pipeline, it
is possible to detect minor variants at a comparable or higher sensitivity than the current ESTA
approach (146-149). The limit of detection of NGS-based genotypic assay is based on the level
of noise, namely the intrinsic combined error rate of the sample preparation procedures and the
sequencing chemistry, which hopefully decreases as the NGS technology advances. Due to its
incredible depth of coverage, NGS-based genotypic testing offers a more detailed, high
resolution picture of quasispecies landscape in patients, allowing doctors to make more informed
decisions (150). In addition, a NGS-based genotypic assay could potential sequence the entire
genome of HIV-1, and detect mutations that confer resistance in multiple viral targets across
different classes of antiretroviral drugs in an all-inclusive multiplex style (151), providing a onestop complete diagnostic and monitoring assay for HIV patient management.
Major disadvantages of the NGS-based genotypic testing include bioinformatic
challenges in data analysis, and prior knowledge of structure-function relationship in result
interpretation (152). In HIV-1 genotypic tropism determination, the latter is especially
challenging, given that the envelope sequence is so variable, and we do not understand all
tropism determinants in gp160 sequence. Currently available computational algorithms,
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Geno2Pheno[coreceptor] and Web PSSM, are designed to make tropism predictions based on the
V3 loop sequence, the major but not only determinant for tropism (153-159). These algorithms
are trained on a limited set of Subtype B sequences that only accounts for 10% of the global
circulating strains, and are not as accurate in other subtypes that account for the majority of HIV1 infections worldwide (160, 161). In addition, even for Subtype B V3 sequences, the algorithms
achieve high specificity (few false positives) but low to moderate sensitivity (many false
negatives) at predicting X4-using variants (162). The current US and European guidelines for
MRV administration based on genotypic testing results predicted by Geno2Pheno[coreceptor]
recommend a false positive rate cut off that ranges from 2 – 5.75% based on MOTIVATE trial
data, up to 10%, highlighting the inadequacy of the current predictive algorithms (163-165). One
potential way to improve the predictive power is to incorporate other non-V3 determinants that
differentiate X4-using variants into the algorithms (166). This requires more research to
understand the structure-function relationship of HIV-1 envelope in the context of coreceptor
binding and specificity. A streamlined, optimized genotypic assay would ideally be highthroughput, fast-turnaround, low cost, and highly specific and sensitive, so more patients eligible
for MRV and other future coreceptor inhibitors could benefit from the respective therapy.
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1.8 Conclusion
Over the past three decades, we have come a long way in understanding HIV biology,
designing optimized treatment methods, and alleviating the morbidity and mortality associated
with the disease. However, HIV/AIDS remain a public health priority today, with 2 million new
cases each year, increasing prevalence of drug-resistant strains, and lack of access to testing and
treatment. The current HAART drugs can effectively suppress viral load and pathology but do
not provide a cure. As a result, HIV patients need to take HAART therapy for the rest of their
lives, raising concerns with long term toxicity and resistance development. Therefore, there is a
continuous need for development of new treatment options and vaccines. Coreceptor inhibitors
are a new class of drugs that could potentially benefit patients if administered properly. Further
understanding of HIV-1 envelope protein interaction with coreceptors could shed light on future
inhibitor design and tropism predictive algorithm improvement.
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1.9 Figures
Figure 1.9.1

Adults and children estimated to be living with HIV by the end of 2014.

An estimated 37 million people are living with HIV worldwide. Approximately 70% of all
people infected with HIV reside in Sub-Saharan Africa.

This figure is adapted from UNAIDS Core Epidemiology Slides (July 2015).
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Figure 1.9.2

HIV-1 replication cycle.

A range of host cell proteins play a role as restriction factors or dependency factors in the process
of HIV life cycle. Different steps in the life cycle are numbered as the following: (1) attachment
and binding to cell surface receptors CD4 and CCR5 or CXCR4; (2) viral fusion and
translocation of viral nucleocapsid into host cell cytoplasm; (3) uncoating of viral nucleocapsid;
(4) formation of reverse transcription complex and reverse transcription; (5) formation of preintegration complex (PIC) and nuclear import of PIC through nuclear pore; (6) integration of
pro-viral genome into host cell genome; (7) transcription from the provirus to make viral
genomic RNA and mRNA; (8) nuclear export of viral genomic RNA and mRNA; (9) translation
of viral mRNA into accessory proteins and structural proteins (gag-pol); (10) assembly of viral
RNA genome and gag-pol on the cell plasma membrane; (167) budding of new virions on the
cell plasma membrane; (12) release of new virions from infected cell membrane via ESCRT
machinery; and (13) maturation of newly release virion into infectious particles via proteolytic
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cleave and rearrangement to form a viral nucleocapsid core. Each of the above steps can be
targeted for intervention. White and blue boxes indicate therapeutic inhibition and cellular
restriction. INSTI, integrase strand transfer inhibitor; LTR, long terminal repeat; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.

This figure is adapted from Alan Engelman and Peter Cherepanov, Nature Reviews
Microbiology 10, 279-290 (April 2012)
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Figure 1.9.3

The multi-step HIV entry process mediated by envelope protein.

The HIV-1 envelope protein in native trimer form (left) is shown with gp41 transmembrane
subunit (blue) and gp120 surface subunit (red). Variable loop regions on gp120 are shown in
yellow and orange. Upon gp120 engagement with CD4 (green) on cell membrane, the variable
loops change conformation, exposing the contact site for the subsequent interaction with
coreceptor CCR5 or CXCR4 (navy). Coreceptor binding results in the insertion of gp41 fusion
peptide (brown) into the cell membrane, which eventually leads to six-helix bundle formation
and membrane fusion (right). Therapeutic and research agents that inhibit the above-mentioned
processes are shown below each step. Ibalizumab (TNX-355) is a monoclonal CD4 antibody that
binds to CD4 and blocks CD4 binding. Maraviroc, Vicriviroc, and TAK779 are CCR5
antagonists that bind to CCR5 and blocks coreceptor interaction. AMD3100 is a CXCR4
inhibitor that blocks CXCR4-tropic viral entry. Enfuvertide (T-20) is a peptide drug that
competitively blocks the formation of six-helix bundle and prevents membrane fusion.
This figure is adapted from Bridgette J. Connell and Hugues Lortat-Jacob, Front. Immunol.(20
November 2013)
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Figure 1.9.4 Envelope gp120 structure and the V3 loop

(A) Schematic representation of HIV-1 envelope gp120, with V3 crystal structure underneath.
The envelope surface subunit gp120 is shown in its primary structure, and annotated with its
conserved regions C1-C5, and variable regions V1-V5. Glycosylation sites are represented as
branches on the primary structure. V3 loop crystal structure for isolate JR-FL is shown in
electron density map. Two cysteine residues C396 and C331 linked by disulphide bridge form
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the base of the V3 loop. The 11 and 25 position on the V3 stem, known to associate with
coreceptor specificity, are annotated as S306 and E322 respectively. The tip of V3 contains a
GPGR motif, annotated by P313 and G314.
(B) Alignment of HIV-1 envelope isolates V3 sequences. The tropism of each V3 loops is
annotated on the side. Conserved residues are shown in red, including the starting and ending
cysteine, as well as the GPGR motif at the tip. Position 11 and 25 are annotated.

This figure is adapted from Tilton JC, Doms RW, Antiviral Res., 2010, Huang C. et al, Science,
2005, and Tan Q et al., Science, 2013.
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Figure 1.9.5

Computational models of HIV-1 envelope-coreceptor interaction.

(A) HIV-1 envelope trimer binding to host cell surface CD4 and coreceptor CXCR4. The
interaction is a multi-subunit conglomerate, with the stoichiometry of gp120, CD4, and
coreceptors not yet clearly defined. Envelope and CD4 are shown as electron density map, while
CXCR4 is shown in cartoon format. The parts are colored as the following: gp120, teal; CD4,
gold; CXCR4, navy. The V3 loops from gp120 are colored red, and the contact residues on
CXCR4 are colored orange.
(B) CCR5-tropic V3 loop (R5-V3) and CXCR4-tropic V3 loop (X4-V3) interaction with CCR5
and CXCR4 extracellular domains respectively are shown superimposed. The V3 loop backbone
makes hydrogen bond with the backbone of extracellular loop 2 (ECL2), while the Proline313 at
the GPGR motif at the tip of V3 makes hydrophobic interaction with the helices of the
coreceptors. The parts are colored as the following: R5-V3, pink; X4-V3, yellow; CCR5, blue;
CXCR4, green.

This figure is adapted from Wang B et al., Science, 2010, and Tan Q et al., Science, 2013.
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Figure 1.9.6 Drug resistance development process in a quasispecies population.

In the context of tropism shift and resistance to coreceptor inhibitors, the starting founder virus
has a R5-topic wildtype phenotype. Upon selection with R5 inhibitors, resistant variants
preferentially expand into the majority of the quasispecies population. Upon therapy withdrawal,
the quasispecies population may demonstrate a reversion into the original R5-topic variants.

This figure is adapted from Kuritzkes DR, PRN, 2004.
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Figure 1.9.7

Illumina next-generation sequencing (NGS) technology work flow.

The steps of Illumina NGS sequencing is the following: (1) random fragmentation of intake
DNA samples, and ligation of adaptor to both ends of the fragments; (2) immobilization of single
stranded adaptor-DNA fragment to the flow cell surface; (3) Solid-phase bridge amplification
using unlabeled nucleotides; (4) formation of several million dense clusters of double-stranded
DNA from Step (3); (5) addition of labeled terminators, primers, and DNA polymerase to start
sequencing cycles. (6) captures of emitted fluorescence from each cluster upon laser excitation as
the DNA elongates; (7) Repeat of Step (5) and (6) to determine the sequence in the DNA
fragment, one base at a time; and (8) Sequences of input DNA fragments as short reads to be
mapped onto a reference sequence for analysis.
This figure is adapted from www.illumina.com
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Figure 1.9.8 Pacific Biosciences third-generation sequencing technology work flow.
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(A) Generation of circular consensus sequences (145) on single DNA molecules. Adaptors
(SMRTbells) are ligated on both ends of double-stranded DNA fragments. Upon denaturation, a
single-stranded circular DNA is obtained for sequencing, DNA polymerase can sequence the
circle multiple passes to generate a consensus sequence of high quality.
(B) SMRT cells for PB system contains zero-mode waveguides (ZMW) that houses single DNA
molecules during sequencing reaction. The DNA polymerase incorporates labeled nucleotides,
and the fluorescence from each ZMW are captured and processed into a DNA sequence (trace).

This figure is adapted from Fichot EB and Norman RS, Microbiome 2013, and
http://www.pacb.com/.
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Chapter 2
Single Clone Analysis of HIV-1 Envelope Quasispecies
Reveals Dynamic Intra-Subject Evolution
with CCR5 Antagonist Therapy
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2.1 Preface
Chapter 2 is adapted from a manuscript prepared for submission. The author
contributions are the following: Lee Ratner and Jie Zhang conceived all the experiments; Jie
Zhang independently performed all the experiments, analyzed all the data, and prepared all the
tables and figures except for Figure 2.11.4(C) and Figure 2.11.7, which are prepared with help
from Xiang Gao; Timothy Henrich and Daniel Kuritzkes kindly provided the clinical samples
used in this study. The manuscript was written and revised by primarily by Jie Zhang and Lee
Ratner.
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2.2 Abstract
HIV-1 envelope interacts with coreceptors CCR5 and/or CXCR4 before gaining entry
into the host cells through a dynamic, multi-step process. The tropism determinants on the
envelope protein are not clearly defined despite recent advances in structural understanding of
the coreceptors as well as the HIV-1 native envelope trimer spike. CCR5 inhibitor treatment in
patients harboring CCR5-tropic virus frequently leads to coreceptor shift and the emergence of
CXCR4-using virus. In order to understand the evolutionary pathways of coreceptor shift, we
examined a panel of single clones from patients before and after they failed CCR5 antagonist
therapy, using a combination of tissue-culture based phenotypic tropism assays and sequencingbased genotypic analysis. We found distinct quasispecies compositions in two study subjects
after the treatment failure. In one of the two subjects, we observed a rapid, complete shift of
tropism and large variations in the envelope variable regions within a two-week period of drug
selection. This study reveals the rapid nature of HIV-1 envelope evolution in vivo, and confirms
key structure-function relationships in envelope coreceptor specificity.
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2.3 Importance
Preventing resistance development to current and future antiretroviral therapeutic agents
is a top priority for global public health against HIV/AIDS. Utilizing a combination of
phenotypic and genotypic assays on 97 single clones isolated from 2 subjects, we confirmed the
previously reported sequence signature for CXCR4 tropism, and cross-validated the structurefunction relationship of existing tropism prediction algorithms. In addition, we demonstrated the
rapid and complete nature of coreceptor shift and treatment escape in one patient, and a slow and
incomplete coreceptor shift in the other patient, under the specific selection pressure of a CCR5
antagonist. This finding suggests different evolutionary pathways about coreceptor shift, and has
implications in clinical administration of coreceptor inhibitors and the need to closely monitor
quasispecies tropism under such therapy.
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2.4 Introduction
C-C chemokine receptor type 5 (CCR5) and C-X-C chemokine receptor type 4 (CXCR4)
are host cell targets for small molecule inhibitors against HIV-1 infection (1-3). After engaging
the primary receptor CD4, HIV virions can utilize either CCR5 (R5), CXCR4 (X4), or both (dual
or R5X4) coreceptors to enter a susceptible cell (4, 5). Blocking virion-coreceptor interaction
stops an infection at the first step of viral replication cycle. Currently, Maraviroc (MRV) is the
first and only FDA approved small molecule CCR5 antagonist against HIV-1 infection, though a
number of other small molecules have been developed and tested as coreceptor inhibitors to both
CCR5 and CXCR4 (6-12). Eligibility for clinical application of MRV requires that a patient
harbors undetectable X4-tropic virus at the commencement of treatment, typically determined by
a tissue-culture based phenotypic method called Enhanced Sensitivity Trofile Assay (ESTA) (13).
Despite the stringent admission criteria, resistance to MRV has been shown to develop in vivo
through multiple potential mechanisms, such as coreceptor shift from R5- to X4-tropism, and
binding to different CCR5 confirmations including the coreceptor-drug complex (14-18).
Resistance development to CCR5 antagonists increases the risk of treatment failure and hampers
the utilization of current and future coreceptor antagonist therapeutic agents (19).
One important factor in the development of resistance to antiretroviral agents lies in the
fact that HIV-1 exists in the host as quasispecies, or a group of genetically related but nonidentical variants (20). An infection typically starts with a few if not a single
transmission/founder virus crossing the mucosal barrier, mostly likely a R5 isolate, and
expansion to more than 106 copies per milliliter of blood a few weeks after infection. During this
rapid course of replication, the virus accumulates mutations as a result of its error-prone RNA
polymerase and high turnover rate, and evolves into a community of quasispecies that is
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adaptable to host and external selection pressures (21). With the memory T lymphocytes being
depleted over the course of the infection, fifty percent of HIV-1 Clade B patients spontaneously
develop X4-tropic virus late in the disease course to more efficiently infect naïve T cells and
bypass inhibitory chemokines produced by HIV-specific cytotoxic T lymphocytes (22).
Administration of a CCR5 antagonist often expedites the coreceptor shift process (23). In some
cases, the development of resistance to a CCR5 antagonist occurred at the cost of reduced viral
fitness, as shown by observed reversion to pre-treatment strains upon the withdrawal of therapy
(24-28). An understanding of the mechanism of coreceptor shift will guide rational design of
better coreceptor inhibitors by blocking the potential paths to resistance development.
Despite recent advances in our understanding of HIV-1 envelope trimer structure and the
structures of both coreceptors through high-resolution crystallography studies, details of
molecular interactions between the envelope and coreceptors remain to be defined (29-35).
Numerous studies have shown that the Variable loop 3 (V3) region of HIV-1 envelope is critical
in coreceptor specificity by making direct contact with extracellular loops of the coreceptors (3638). Regions outside V3, including the C2-V5 regions, that have been shown to regulate
coreceptor tropism include specific residues at position 440 in C4, and regions in gp41 (Chapter
3) (39-42). Study of coreceptor antagonist resistant variants allows us to identify key envelope
determinants for resistance development and coreceptor shift, especially in the context of a
defined selection pressure (17, 43-47).
To better understand the evolutionary process of HIV-1 envelope quasispecies that led to
drug resistance and coreceptor shift in vivo under the selection of a CCR5 antagonist, we
analyzed a panel of 97 HIV-1 envelope single clones from 4 samples from 2 subjects who
experienced treatment failure in a clinical trial for a CCR5 antagonist Vicriviroc (VCV). Using a
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combination of phenotypic tropism assays and genotypic analysis, we showed a rapid change of
tropism upon VCV treatment and detected signature changes in envelope V3 regions that
correspond to the phenotypic coreceptor shift.
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2.5 Materials and Methods
2.5.1 Patient samples
HIV-1 envelope amplicons were obtained from participants in a Vicriviroc (VCV) Phase
II clinical trial (AIDS Clinical Trials Group [ACTG] A5211; NCT00082498) (48). Participant
selection and sample preparation were described previously (Manuscript Zhang et al) (49).
Plasma samples were collected from study participants who experienced virologic failure and
had tropism change by the phenotypic Trofile assay (Monogram Biosciences). Pelleted virion
RNA was used to prepared env cDNA. Envelope amplicons were generated using previously
reported primers (50):
Env1Atopo (5’-CACCGGCTTAGGCATCTCCTATGGCAGGAAGAA-3’)
FLenv2.2 (5’-AGCTGGATCCGTCTCGAGATACTGCTCCCACCC-3’)

2.5.2 Single Clone Isolation
Patient envelope amplicons were cloned into expression vectors in frame. Two
approaches were taken to generate single clones from patient samples. The first approach cloned
patient envelope amplicon PCR products into pcDNA3.3-TOPO, a TA cloning vector containing
a CMV promoter, by following the manufacturer’s protocol (Thermal Fisher Scientific). The
TA ligation reaction was prepared using QiaQuick PCR purification columns following the
manufacturer’s protocol (Qiagen) and electroporated into ElectroMAX Stbl4 competent cells
(Thermo Fisher) in 1 mm cuvette at 1.2 kV, 25 µF, 200 Ω mA on BioRad MicroPulser (BioRad).
Transformants were recovered in 1 mL of S.O.C. medium by shaking at 30 °C for 90 minutes at
225 RPM, and 20 – 100 L was plated on Luria-Broth (LB) agar plates supplemented with 150
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g/mL of ampicillin (Sigma-Aldrich). Single colonies were separately transferred and grown in 3
mL of LB liquid media containing 150 g/mL of ampicillin (Sigma-Aldrich) by shaking at 30 °C
at 225 RPM for 18 – 20 hours. The resultant culture was used to prepare plasmid DNA using
PureLink Quick Plasmid Miniprep Kit (Thermal Fisher Scientific). The single clone plasmids
were screened for the presence or absence of the insert patient envelope gene and for the
orientation of the insert using PCR using the following combinations of directional primers.
CMV-forward: 5’-CGCAAATGGGCGGTAGGCGTG-3’
TK polyA-reverse: 5΄-CTTCCGTGTTTCAGTTAGC-3΄
Env1Atopo-forward: 5’-CACCGGCTTAGGCATCTCCTATGGCAGGAAGAA-3’
FL-Env2.2-reverse: 5’-AGCTGGATCCGTCTCGAGATACTGCTCCCACCC-3’
A 3kb product with CMV-forward and TK polyA-reverse, and Env1Atopo-forward and FLEnv2.2-reverse primers confirmed the presence of HIV-1 envelope amplicon insert in pcDNA3.3
vector. A 3kb product with CMV-forward and FL-Env2.2-reverse primers confirmed that the
envelope gene is inserted in the forward orientation downstream of the CMV promoter, whereas
products with TK polyA-reverse and FL-Env2.2-reverse indicated a reverse orientation,
unsuitable for follow-up expression experiments. Only pcDNA3.3-TOPO-CMV-Env clones
containing an envelope gene insert in the correct orientation were used in pseudotyping
experiments to test the functionality of individual envelope isolates.
The second approach directly cloned patient amplicon samples in frame into HIV-1
molecular clone pNL4-3.Luc.R–.E– (Dr. Nathaniel Landau, the NIH AIDS Reagent Program) to
generate replication competent viral molecular clones in a directional manner, using Gibson
Assembly® Master Mix (New England Biolabs) according to the manufacturer’s protocol (51,
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52). An AfeI site (AGCGCT) that does not alter the amino acid sequence was introduced at
nucleotide 5954 of pNL4-3.Luc.R–.E– by site directed mutagenesis. A NotI site is present in the
vector at the 4th codon of nef, the position in which the luciferase gene was inserted. The vector
was linearized using AfeI and NotI. The insert was prepared by PCR amplification of the patient
envelope amplicons using the following primers:
NL4-AfeI-EnvF:
5’-TTGTTTCATGACAAA AGCGCT AGGCATCTCCTATGGCAGGAAG -3’
NL4-NotI-EnvR:
5’- TTTTGGCGTCTTCAGCGGCCGCGCCACCCATCTTATAGCAAAATCCTTTC -3’
The PCR was performed with Q5 High-Fidelity 2× Master Mix (New England Biolabs)
following the manufacturer’s protocol, and run on BioRad T100 thermal cycler (BioRad) using
the following conditions: 98°C for 30 sec; 15 cycles of 98 °C for 10 sec, 55 °C for 20 sec, and
72 °C for 2 min; and 72°C for 5 min. The PCR product included flanking regions of pNL43.Luc.R–.E–. The Gibson assembly reaction was performed with an insert to vector ratio of 3:1 at
50 °C for 60 minutes. The assembly product was diluted 1:3 and electroporated into
ElectroMAXTM Stbl4TM competent cells as described above, and single clone were selected in
the same manner for the first approach. Colony PCR and diagnostic restriction digestion were
performed to screen for clones containing an insert. Plasmid DNA prepared as described above
were used in tissue-culture based phenotypic functional assays as well as genotype sequencing.
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2.5.3 Cell Lines
HEK 293T cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM)
supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, and 1x
antibacterial, antimycotic solution (containing 100 U/mL penicillin, 100 g/mL streptomycin,
and 250 ng/mL amphotericin B). U87.CD4 cells were stably transfected with pBABE-CCR5GFP or pBABE-CXCR5-GFP, constructed as previously described, and maintained in DMEM
supplemented with 15% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 1x
antibacterial, antimycotic solution, 0.2 mg/mL G418, and 1 g/mL puromycin (53).

2.5.4 Virus production
Pseudotyped HIV-1 virions containing individual envelope variants were produced by cotransfection of 5 g of HIV-1 molecular clone pNL4-3.Luc.R–.E– plasmid DNA and 0.5 g of
pcDNA3.3-TOPO-CMV-Env into 4×105 HEK 293T cells in a 6-well plate format using 10 L of
TransIT®-LT1 Transfection Reagent (Mirus). Replication-competent HIV-1 containing
individual envelope isolates were produced by transfecting 5 g of the molecular clone plasmid
DNA as described above. The viral supernatant was harvested at 48 to 72 hours post transfection
and passed through a 0.44 m syringe filter to remove cell debris.

2.5.5 Luciferase-based infection assay
Freshly prepared viral stocks were used to infect U87.CD4.CCR5 and U87.CD4.CXCR4
cells in the presence of 8 g/mL DEAE dextran, as previously described (53). U87.CD4.CCR5
and U87.CD4.CXCR4 cells were plated in 96-well plates at 104 cells in 100 L of media per
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well 24 hours before infection. During infection, 100 L of freshly harvested viral supernatant
was added to each well in triplicates, and incubated with cells at 37 °C, 5% CO2, and 95%
humidity for 12 hours. The virus was removed 12 hours after the start of infection, and the
infection was continued in fresh media for another 36 hours to allow for expression of luciferase
in the infected cells. Cells were harvested 48 hours post-infection and lysed with 0.2% TritonX100 (Sigma-Aldrich) in PBS. The cell lysates were read for luciferase activity on an Optocomp
I luminometer (MGM Instruments). A result was scored as positive if the relative light unit
readout was more than 2 standard deviations over the mean of mock infected control wells. Cells
infected with pNL4-3.Luc.R–.E– pseudotyped with vesicular stomatitis virus G glycoprotein
envelope was used as the positive control, and cells infected with pNL4-3.Luc.R–.E– alone was
used as the negative control.

2.5.6 Flow cytometry
The coreceptor-expressing U87-CD4 cells were stained with anti-CD4 antibody (clone
Q4120) conjugated with phycoerythrin (Sigma-Aldrich), anti-CXCR4 antibody (clone 12G5)
conjugated with allophycocyanin (BioLegend), and anti- CCR5 antibody (clone 2D7) conjugated
with allophycocyanin at 4 °C in the dark for 20 minutes according to manufacturer’s protocol
(BD Pharmingen, BD Biosciences), washed with PBS three times, resuspended in 5% FBS in
PBS, fixed with 2% paraformaldehyde, and run on FACSCalibur (BD Biosciences). Flow
cytometry data were visualized with Flowing Software version 2.5
(http://www.flowingsoftware.com/).
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2.5.7 Sequence alignment and phylogenetic analysis
Pairwise and multiple sequence alignments were performed using Needle
(http://www.ebi.ac.uk/Tools/psa/emboss_needle/) and Clustal Omega
(http://www.ebi.ac.uk/Tools/msa/clustalo/) on the European Bioinformatics Institute website.
Phylogenetic trees of envelope variants were generated using PhyML
(http://www.hiv.lanl.gov/content/sequence/PHYML/interface.html) or Clustal Omega with
Pearson/FASTA output and iTOL (http://itol.embl.de/). Evolutionary analyses of specific
envelope regions via calculating dN/dS ratio were performed using Synonymous Nonsynonymous Analysis Program (54) on the HIV database website
(http://www.hiv.lanl.gov/content/sequence/SNAP/SNAP.html).

2.5.8 Tropism prediction
Tropism prediction was performed using the online version of Geno2Pheno[coreceptor]
2.5 following the developer’s instructions at http://coreceptor.geno2pheno.org/. Only the
Variable loop 3 (V3) region sequences were used for tropism prediction.
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2.6 Results
2.6.1 Evaluation of HIV-1 patient samples by single clone analysis
HIV-1 patient samples were collected from eight study subjects at two time points on
ACTG A5211 Phase II study of vicriviroc (VCV) (Zhang et al, manuscript). Based on the
original phenotypic Trofile assay results, at study initiation, participants harbored viruses that
used exclusively or preferentially CCR5 (Time point 1 at Week 0). At the second time point,
these individuals experienced protocol-defined virologic failure, defined as less than 1 log10
decrease of HIV-1 RNA level. At this time point, plasma env amplicons demonstrated the ability
to utilize CXCR4 for entry, and their tropism was designated as dual-mixed (DM). The time
elapsed between the first and second time points varied among the study subjects from 2 to 32
weeks.
In order to define the phenotypes of quasispecies present in these samples, we isolated
single clones from the library of HIV-1 envelope patient amplicons and performed in-depth
phenotypic and genotypic characterization of individual envelope-expression clones (Figure 1).
The TOPO TA cloning technology offered an approach to clone a mixture of similar-sized
envelope amplicon PCR products into a CMV-promoter driven expression vector and to isolate
bacterial single colonies after transformation. We assumed that one transformed bacterial colony
contains a single ligated vector that contains one inserted HIV-1 env gene from the original
patient amplicon samples. Therefore, the single colonies represent independent sampling of the
pool of quasispecies in the original patient sample, offering a glimpse of the viral variants in the
bloodstream of the patients at different times, during the course of VCV treatment. By sampling
sufficient numbers of single clones, we defined the distribution of quasispecies variants, their
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respective tropisms, and sequence similarities or differences, in order to define structure-function
correlations of the envelope protein and its role in coreceptor specificity.
From the sixteen samples coming from eight study subjects, we selected four samples
from two subjects for the single clone analysis. We chose to focus on these two subjects because
their samples demonstrated different lengths of time for coreceptor shift. Subject 1 showed high
R5-tropic viral activity at baseline, and comparable R5- and X4-tropic activity in only two weeks.
In contrast, samples from Subject 2 remained predominantly R5-tropic at Week 0 and Week 8,
but also showed significantly increased X4-tropism at the second time point based on the
luciferase assay readings in the Trofile assay (Subjects 1 and 2, Figure 4A). The difference in
times required for coreceptor-shift might relate to distinct evolutionary pathways to switch from
R5-tropism to dual- or X4-tropism.

2.6.2 Phenotypic analysis of single clones consistent with Trofile results
We established a tissue-culture based luciferase-reporter infection assay that is similar to
the bulk-screening Trofile assay. The luciferase-based infection assay consisted of producing
pseudotyped or replication competent virions that expressed luciferase in place of Nef by
transfecting 293T cells, and reading luciferase activity as an indicator of viral entry from infected
U87.CD4.CCR5 or U87.CD4.CXCR4 cells (Figure 1). We generated U87.CD4 cell lines stably
transfected and expressing CCR5-GFP or CXCR4-GFP fusion proteins on their surface (53).
These cell lines expressed comparable levels of CD4 and coreceptor based on surface staining
and GFP expression (Figure 2). The activity of envelope expression clones to utilize CD4 and
one of the two coreceptors was quantified by luciferase measurements reported as relative light
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units (RLUs). A representative luciferase-based infection assay result is shown in Figure 3. In
this experiment, six out of eight clones from Sample 1.2 were functional and dual-tropic, while
the other two clones were non-functional, defined as being unable to enter either X4- or R5expressing U87.CD4 cells.
Using the aforementioned phenotypic assay, we characterized a total of 97 single clones
from four samples, including 6 clones from Sample 1.1, 46 clones from Sample 1.2, 10 clones
from Sample 2.1, and 35 clones from Sample 2.2 (Figure 4B-C). The outcome was consistent
with the Trofile assay results which examined plasma viral samples in bulk. At the first time
point, only R5-tropic quasispecies for Subjects 1 and 2 were found. At the second time point, 65%
of single clones from Sample 1.2 were R5X4-tropic, and the remaining clones were nonfunctional. In contrast, in Sample 2.2, 17% of clones were R5-tropic, 20% of clones were R5X4tropic, and 63% of clones were non-functional. .

2.6.3 Quantitation of molecular cloning artifact using laboratory adapted molecular clones
To control for mutations generated through the molecular cloning process, two lab
adapted HIV-1 molecular clone strains p102 (pNL4.3) and p125 were processed in parallel with
the patient amplicon samples. With the TOPO cloning approach, p102 and p125 envelope PCR
products were ligated into pcDNA3.3-TOPO-CMV vector. Single clones were isolated and
tested for phenotypic functionality in the luciferase-based tropism assay, as well for genotypic
variation via sequencing. We observed on average 12.5% of single clones being non-functional,
and there were minimal numbers of sequence variations among the non-functional control single
clones (Table 1). With the Gibson Assembly (GA) clone approach, we performed three sets of
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GA ligation using envelopes from p102, p120, and 1:1 mixture of p102 and p120 as inserts.
After quality control using colony PCR and diagnostic restriction digestion, the clones that were
confirmed to have an insert with intact restriction sites were used in phenotypic functional testing.
Out of all 23 clones tested from three sets combined, 3 clones were non-functional, resulting in a
13.0% non-functional rate due to cloning artifacts (Table 1). The level of non-functional clones
and sequence diversity observed in the controls was 3-5 folds lower comparing to the level of
non-functional clones and sequence diversity present in the single clones isolated from patient
amplicon samples. Therefore, the striking sequence variations observed in Sample 1.1 and 1.2
single clones were unlikely an artifact introduced by molecular cloning, but most likely reflects
the sequence variation in viral quasispecies present in vivo within the patients.

2.6.4 Single clones within one time point were highly similar in sequence
To understand the structural determinants that affect coreceptor specificity, envelope
clones were subjected to sequence analysis. Alignment of clones from Sample 1.2 by Clustal
Omega showed a strong selection pressure towards two major variants (Figure 5). Among the six
clones, four of them exhibited identical amino acid sequences. One of the four contained two
synonymous mutations. Spanning the length of the partial variable loop 2 (V2) region, and the
complete V3 and V4 regions, there were in total four positions that differed among the six clones.
Examination of the V3 region revealed that all of six clones from Sample 1.2 bear signature of
X4-utilization, including a glycine at the 11th position, a lysine at the 25th position, and overall
positive charge of +8. Prediction of tropism, using the Geno2Pheno[coreceptor] algorithm,
correctly identified all six clones to be X4-tropicwith a low false positive rate. Overall, the
variants from Sample 1.2 have all been shown to be dual-tropic, and the V3 signatures were
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consistent with functional characterization, based on previous studies. Moreover, there was a
lack of diversity among the variable regions of the six clones from Sample 1.2, suggesting a
strong selection pressure towards one particular genotype. These suggested that it might be
advantageous for this virus subtype for replication in the presence of CCR5 inhibitor VCV,
resulting in rapid change to an abundant circulating genotype within just two weeks of treatment.

2.6.5 Genotypic analysis of single clones over time shows great diversity
Longitudinal analysis of variant sequences from before and after VCV treatment of the
same subject revealed significant quasispecies changes over time (Figure 6). Examination of the
alignment showed that amino acid substitutions mostly concentrated in variable regions V2, V3,
and V4. Insertions and deletions were found exclusively in the V2 and V4 region. The
conserved regions also contained amino acid substitutions which were located more sparsely
than those in the variable regions. The V3 regions from samples before and after treatment
showed sequence signatures that corresponded to R5- and X4-usage. In particular, the 25th
position in the V3 region was a negatively charged glutamic acid in the R5-tropic Sample 1.1
clone we sampled, whereas it was converted to a positively charged lysine in the X4-tropic
Sample 1.2 clone. This observation was consistent with previous reports that the variant is more
likely to use CXCR4 if there is at least one positively charged residue at the 11th and 25th
position (glycine and glutamic acid in the 1.1 clones; glycine and lysine in the 1.2 clone;
highlighted in Figure 6) of V3. Genotypic analysis of the V3 region of these two clones
demonstrated sequence signatures corresponding to a change of coreceptor specificity and was
consistent with the luciferase-based phenotypic tropism assay results for these two clones,
respectively.
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In addition, a quantitative analysis of the alignment revealed a high level of sequence
diversity in the V2-C3-V3-C4-V4 regions between a major clone from Sample 1.2 and one
representative clone from Sample 1.1 (Table 1). On average, 19 – 20% of sequences were
different in these two clones through the above mentioned regions. The variable regions showed
over 20% of sequence differences, with the V4 region being the most variable (36 – 41% of
sequences being different). The conserved regions C3 and C4 were less variable as expected,
with 13% of sequence diversity between the two clones from before and after treatment.
Typically, the intra-clade env sequence variability was reported to be 10 – 15% among all
circulating strains. One longitudinal study also showed that viral V3 sequences in chronically
infected individuals stayed largely constant over time, with limited within-person evolution.
Therefore, it was surprising to discover a much higher percentage of sequence variation in
Subject 1 from single clones that arose over a relatively short time period of two weeks.

2.6.6 Phylogenetic analysis of envelope sequences consistent with their phenotypic function
To dissect the evolutionary relationship between the HIV-1 env single clones, we
generated a maximal parsimony (MP) tree using the V3 regions from the six single clones from
Sample 1.2 and the single clone from Sample 1.1 (Figure 7). The lab-adapted strain HXB2 that
uses CXCR4 exclusively for entry was included as a reference. The MP tree showed clustering
of dual-tropic clones from Sample 1.2 together on a single branch and away from the R5-tropic
clones from Sample 1.1. HXB2 sequence was furthest away from the patient sample clones.
Overall, the sequence based phylogenetic analysis was consistent with the phenotypically
validated tropism of these single clones, suggesting sequence-based analysis of envelope could
be a valuable tool in predicting functional tropism. In addition, single clones that were close on a
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phylogenetic tree but potentially with discordant tropisms could offer insights in important
determinants in coreceptor shift.
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2.7 Discussion
In this study, we utilized a rapid, reliable sampling method to isolate a large number of
single clones from clinical trial subjects who developed resistance to VCV therapy. By
performing tissue-culture based phenotypic assay and sequencing-based genotypic analysis on
single clones, we were able to probe the viral quasispecies before and after VCV treatment in
vivo, and understand how the HIV-1 envelope evolves in the face of a specific CCR5 antagonist
selection. The advantage of the single clone analysis rested in the ability to fully characterize
each individual clone and interrogate the structure-function relationship of HIV-1 envelope by
making associations between key sequence determinants and its specific tropism status. In
addition, the availability of the full-length envelope sequence allowed for investigation of nonV3 determinants in the process of coreceptor shift, and phylogenetic studies looking at clones
before and after coreceptor shift would potentially shed light on the evolutionary pathway for
this process.
Single clone isolation and analysis from patient samples is an established and widely
used approach in studying HIV-1 quasispecies. Depending on the cloning and screening
methodology, single clone analysis with a large enough sampling size provides a survey of the
quasispecies composition in vivo at different time points. A caveat with our approach using the
pcDNA3.3-TOPO-CMV was a potential bias in the directional TOPO cloning strategy. We
observed approximately 70 – 95% of reverse-orientation insert, much higher and statistically
significant ( p<0.01 by Chi square test), than the predicted 50% chance if the insertion
orientation were truly random. This could potentially be due to a selection against envelope gene
inserted in the correct orientation downstream of the CMV promoter. A plausible speculation is
that expression of envelope protein, even at a low level from a eukaryotic promoter, in Stbl4
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bacterial cell leads to toxicity or cell death. There were previous reports on the leakiness of CMV
promoter in prokaryotic systems (55). This would also result in an enrichment of non-functional
clones that harbor premature stop codon and do not produce full-length, functional envelope
protein. To mitigate this potential pitfall, we adopted a Gibson Assembly ligation system that
directly cloned patient envelope amplicons into a HIV-1 molecular clone. Since the HIV-1 LTR
is a much weaker promoter in E. coli, the problem from toxicity of aberrantly expressed viral
gene products should be largely alleviated if not completely eliminated. Single clones from
Subject 2 were isolated using the latter approach.
In the phenotypic analysis, we observed a significant proportion of non-functional single
clones, ranging from 50% in Sample 1.1, 35% in Sample 1.2, to 60% in Sample 2.1 and 63% in
Sample 2.2. Given that we observed a 12.5% non-functional rate in the lab adapted p102 and
p125 control experiments, the large percentage of non-functional single clones cannot be
attributed to cloning artifacts alone. A plausible explanation is that these single clones are a
natural product of viral replication. Since these patients did not have effective suppression of
viral replication, the virus was actively replicating despite of the antiretroviral therapy. The high
mutation rate of viral reverse transcriptase combined with a rapid viral turnover rate could
produce numerous mutations in the progeny virus, many of these mutations being deleterious in
nature by chance. In addition, a recent latency study showed that the viral quasispecies present in
the peripheral blood are more likely to be defective and non-infectious in nature, comparing to
the quasispecies in the latently infected compartment in the lymphoid organs (56). This is based
on the observation that in chronically infected patients on HAART, there are more clonally
expanded, dividing T cells that harbor defective provirus and release them to the circulation, in
contrast to quiescent, non-dividing memory T cells where the replication-competent virus
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mostly reside. Therefore, the large fraction of non-functional single clones we detected is likely a
true reflection of the viral quasispecies landscape in the plasma of the treatment-experienced
study participants.
From the phenotypic and genotypic analysis of the single clones from Sample 1.1 and 1.2,
we observed a complete shift of tropism from R5-tropic to dual-tropic clones, as well as two
representative sequences that were, on average, 20% different. This dramatic change in tropism
and sequences of quasispecies suggested rapid expansion of one or a several related dual-tropic
quasispecies during the two weeks of VCV treatment. In addition, the six clones sequenced from
Sample 1.2 were highly similar, suggesting a strong selection pressure towards this homogenous
genotype. Overall, a phylogenetic analysis of the 1.1 and 1.2 clones showed that clones with
similar functional tropism status were also evolutionarily closer to each other than clones with a
different tropism. By analyzing the functions and sequences of individual clones, we were able to
gather important information on the evolution of HIV-1 envelope quasispecies in the context of
coreceptor inhibitor treatment.
On the other hand, the single clones from Subject 2 showed mixed tropism even after
VCV treatment. More detailed analysis of the 2.1 and 2.2 clones, such as dN/dS analysis on the
full-length, variable and conserved regions of the envelope sequence, and maximal parsimony or
neighbor joining tree analysis, are needed to understand the evolutionary relationship between
these clones, and the potential drug-resistance mechanism of the R5-tropic clones from Sample
2.2. A pair of evolutionarily close clones with discordant tropism status would potentially reveal
the critical difference that leads to coreceptor shift from R5- to X4-usage.We have not been able
to detect such a pair in the single clone analysis, likely due to the limited sample size. It is
possible that we could detect such pairs of sequences using deep sequencing approaching.
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Alternatively, such tropism-shift intermediate clones might not be detected at all in the patient
plasma samples, if the viral quasispecies undergone the mutational process largely reside in
latently infected reservoir or lymph tissues that are not sampled in this study. This is due to the
fact that
One disadvantage of the single clone analysis lies in its power of this analysis, in
particular when the number of single clones sampled is insufficient to provide an accurate
representation of the pool of quasispecies. In this study, we analyzed a relatively large number of
single clones from the samples of the second time point, post VCV treatment failure.
Additionally, we performed next generation sequencing (NGS) experiments that systematically
examined the quasispecies community (Chapter 3), which complemented and validated the
single clone analysis. The combination of depth from the single clone analysis and breadth from
the deep sequencing analysis provides a comprehensive understanding of envelope evolution in
vivo and the key determinants associated with coreceptor shift. The new information of the
structure-function relationship of HIV-1 envelope and the mechanism of coreceptor shift could
potentially provide new prognostic tools for HIV-1 infected patients, as well as new insights
applicable to coreceptor inhibitor design.
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2.10 Tables
Table 2.10.1. Summary of phenotypic and genotypic analysis for control single clones
Strains

Tropism

Number of Clones

Non-functional

Mutations*

TOPO TA cloning with pcDNA3.3-TOPO-CMV vector
p102**

X4

12

2

5 substitutions in 2 clones

p125***

R5

12

1

3 substitutions in 1 clone

Gibson Assembly cloning into pNL4.3 E-R-Luc vector
p120

X4

8

2

N.D.****

p125

R5

8

1

N.D.

p102 / p125
(1:1)

X4 and
R5

7

0

N.D.

*Mutations: all the mutations observed in the non-functional full-length envelope clones.
** p102:NL4.3 laboratory adapted strain
***p125: NL-HXADA-GG, 2.7 kb of SalI-BamHI (5785-8474) HXADA sequence into p102
NL4.3 backbone; HXADA comprises of BglII-BglII (7040-7620) ADA sequence into HXB2
backbone.
****N.D.: not determined
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Table 2.10.2. Sequence comparison between one major clone from 1.2 and one clone from 1.1

+

Regions*

Length**

Substitutions

Diversity***

Indels

V2 through V4

272 – 279

53

19 - 19.5%

6

V2

57 - 59

13

22 – 22.8%

2 (-4, +6)

V3

35

8

22.9%

0

V4

29 - 33

12

36.4 – 41.4%

3 (+1, -1, -4)

C3 and C4 combined

151 - 152

20

13.2%

1

*Regions: Variable loop 2, 3 and 4 (V2, V3 and V4) as shown in Figure 6. Conserved regions 3
and 4 (C3 and C4) are located between V2/V3, and V3/V4 respectively.
** Length (Lackner, #2553): length of the specified regions in amino acid. In the case of
insertions and deletions, the length of the particular region is shown as a range.
***Diversity: calculated as number of amino acid substitutions divided by the length of the
region, presented in percentage.
+

Indels: insertions and deletions. The number of indels and their nature are presented. For

example, in V2 region, there are 2 indels; one is a 4 amino acid deletion, the other is a 6 amino
acid insertion.
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2.11 Figures
Figure 2.11.1 Schematic diagram of the experimental design.

Patient derived envelope quasispecies amplicons were cloned into (1) pcDNA3.3-TOPO-CMV
expression vectors, or (2) NL4.3Env-luc+ reporter vector (plasmid libraries) and expressed in
293T cells as (1) pseudotyped or (2) replication competent virions that were used to infect
coreceptor expressing cell lines in the presence or absence of coreceptor inhibitors. Infected cells
were lysed and read for luciferase activity as an indicator for infection. Approximately 50 clones
were screened for each patient sample. The envelope genes from the single clones were also
analyzed by Sanger sequencing.
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Figure 2.11.2

Coreceptor-GFP cell lines express comparable levels of CD4 and

coreceptors on the surface.

A

Unstained
Unstained
U87.CD4
Unstained
U87.CD4.CXCR4
U87.CD4.CCR5

B U87.CD4.CXCR
4

U87.CD4.CCR
5
Unstained
hCD4PE
hCXCR4-APC
hCCR5-APC

(A) Unstained U87.CD4.CXCR4 (X4) and U87.CD4.CCR5 (R5) cell lines show similar level of
GFP expression comparing to the parental U87.CD4 cell line.
(B) X4 and R5 cell lines show comparable levels of surface CD4 staining as well as positive
CXCR4 and CCR5 surface expression by flow cytometry comparing to unstained or negative
controls. Different levels of mean fluorescence intensity for CXCR4 staining on X4 cells and
CCR5 staining on R5 cells are likely due to the inherent difference between the two conjugated
antibodies against these surface antigens, and not a reflection of the coreceptor surface
expression levels.
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Figure 2.11.3

A representative luciferase-based phenotypic tropism assay for envelope

single clones.

Out of 46 envelope single clone from Sample 1.2 tested, 8 clones are shown here. RLU: relative
light units. D: dual-tropic, ability to enter using both X4 and R5 coreceptors. N.F.: nonfunctional, the inability to use either X4 or R5 for entry. Negative controls include mock
transfection without DNA and mock infection with non-pseudotyped NL4.3-Luc Env knockout
virus. Positive control was NL4.3-Luc.R-.E- pseudotyped with VSV-g envelope. Out of the
eight clones shown in this experiment, six of them are functional and can infect both CXCR4 and
CCR5 expressing cells.
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Figure 2.11.4

Summary of single clone tropism analysis.

(A) Tropism analysis from bulk patient sample. Subject: HIV-1 patients who experienced
virological failure (defined as smaller than 1 log10 viral load decrease at or after week 16 by
protocol) in a Vicriviroc phase IIb clinical trial. RLU: Relative Light Units by the original
luciferase-based Trofile assay on CCR5 (R5) or CXCR4 (X4) expressing cell lines. Tropism: the
ability of the virus to utilize R5 and/or X4 for viral entry. DM: dual/mixed tropism. Dual
tropism: the ability to utilize both R5 and X4 for entry; mixed tropism: coexistence of viral
species that can use either R5 or X4 coreceptor for entry.
(B) Single clone tropism analysis for Sample 1.1 and 1.2. (C) Single clone tropism analysis for
Sample 2.1 and 2.2.
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Figure 2.11.5 Variable loop region sequence analysis among 6 clones from Sample 1.2.

Partial sequences of V2, complete sequences of V3 and V4 from six 1.2 clones were aligned at
both nucleotide and amino acid level. Four clones (2, 13, 14, and 22) are identical at amino acid
level, though two synonymous mutations were found in clone #2. Clone #4 and #7 contains four
non-synonymous mutations total (annotated by asterisk * and minor variants labelled with
th

th

squares). The 11 and 25 position in the V3 loop were highlighted and contain a glutamic acid
and lysine residue respectively.
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Figure 2.11.6

V2 through V4 region sequence analysis between a major clone from

Sample 1.2 and a single clone from Sample 1.1.

Non-synonymous mutations are annotated with asterisk (*). The 11th and 25th position in the V3
loop were labelled by black squares. Numerous substitutions, deletions, and insertions were
detected between the single clone from 1.1 and the major clone form 1.2
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Figure 2.11.7

Maximal parsimony tree based on V3 sequences for six Sample 1.2 clones,

one Sample 1.1 clone and HXB2

The analysis was performed with 100 iterations. Boot-strapping values are displayed next to the
nodes between the neighboring leaves or branches. Phenotypically validated tropism was
annotated on the side. D: dual-tropism. R5: CCR5-tropism. HXB2: a lab adapted reference strain
that utilizes X4 for entry. The tree was built and visualized using PhyML on HIV database
website.
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Chapter 3
Deep Sequencing Analysis show Evolution of Coreceptor Utilization
to Escape CCR5 Antagonist Therapy
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3.1 Preface
Chapter 3 is adapted from a manuscript submitted for publication on October 20th, 2015.
The author contributions are the following: Lee Ratner and Jie Zhang conceived all the
experiments and analysis; Jie Zhang and Xiang Gao generated all the plasmid libraries; Xiang
Gao generated all the functional libraries; Jie Zhang and Zheng Chen developed approaches for
sequencing data alignment, reads extraction, and entropy analysis; John Martin performed all the
sequencing data quality control, alignment, and reads extraction. Jie Zhang analyzed all the
processed data, and prepared all the tables and figures except for Figure 3.11.4 and Figure 3.11.5,
which were prepared by John Martin and Bruce Rosa; Makedonka Mitreva provided intellectual
suggestion and support for the sequencing process; Timothy Henrich and Daniel Kuritzkes kindly
provided the clinical samples used in this study. The manuscript was written and revised by
primarily by Jie Zhang and Lee Ratner; Zheng Chen, Makedonka Mitreva, and Daniel Kuritzkes
provided useful comments.
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3.2 Abstract
HIV-1 envelope interacts with coreceptors CCR5 and CXCR4 in a dynamic, multi-step
fashion. Lack of detailed understanding of the molecular mechanism of envelope-coreceptor
interactions hampers efforts to design more effective and precise entry inhibitors. Clinical
application of CCR5 antagonists often results in tropism shift and subsequent therapeutic failure
in patients. Using plasma from individuals whose virus escaped a CCR5 antagonist therapy, we
constructed libraries of replication competent proviral clones that contain full-length patientderived env amplicons. Tropism of quasispecies was determined by cell-based functional assays
in vitro. Deep sequencing analysis revealed novel non-V3 region determinants that correlated
with differential use of CCR5 and CXCR4. In particular, we identified important residues
located on the gp120-gp41 interaction surface within one gp160 subunit, and on the gp41-gp41
contact surface between two neighboring gp160 subunits in a trimeric spike structure. Through
in-depth analysis of functionally validated full-length envelope sequences, this study identifies
important structure-function relationship within HIV-1 envelope and provides mechanistic
insight into coreceptor specificity.
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3.3 Importance
Preventing resistance development to current and future antiretroviral therapeutic agents
is a top priority for global public health against HIV/AIDS. Utilizing next-generation sequencing
approaches and phenotypic assays, we show a detailed picture of quasispecies evolution and
treatment escape in vivo under the specific selection pressure of a CCR5 antagonist. We
identified important regions in full-length gp160 that correlate with CXCR4 usage, in particular
the regions at gp120-gp41 and gp41-gp41 interaction surfaces. This new line of evidence
suggests a new hypothesis about coreceptor shift, and potentially has implications in coreceptor
inhibitor design and tropism predictive algorithm development.
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3.4 Introduction
Infection by human Immunodeficiency Virus Type 1 (HIV-1) is initiated by viral
envelope trimer binding to the host cell receptor, CD4, and subsequently one of the two
coreceptors C-C Chemokine Receptor Type 5 (CCR5) or C-X-C Chemokine Receptor Type 4
(CXCR4). A series of step-wise, dynamic conformational changes occurs following the two
binding events which culminates in viral and cell membrane fusion, and release of the
nucleocapsid core into the host cell (1, 2). The ability of a virion to bind either one or both
chemokine receptors for entry has significant implications in disease pathogenesis, and affects
treatment options (3). Although nearly all founder / transmitter viruses are strictly CCR5-tropic
(termed R5 virus), close to 50% of HIV-1 subtype B patients will spontaneously develop
CXCR4-using (X4) virus as the disease progresses, and the presence of X4 virus correlates with
a worse clinical prognosis (4). This observation is thought to reflect the bottleneck nature of
HIV-1 transmission, a preferential targeting of previously activated memory T lymphocytes in
the early phase of infection, and the push to infect naïve T cells late in the disease course when
the majority of memory T cells have been depleted (5). The process of coreceptor shift that
otherwise naturally occurs with disease progression can take an expedited course upon the
administration of a CCR5 antagonist antiretroviral drug (6). This limits the therapeutic
application of CCR5 antagonists in patient management, and requires meticulous tropism
determination prior to administration of the drug (7, 8).
Numerous studies examined the structural aspects of HIV-1envelope and coreceptor
interaction (9-12). There has been a continuing effort to determine the viral envelope protein
structure in its ligand-free, mature trimer configuration, as well as in complex with neutralizing
antibodies (13-15). Recently, high-resolution crystal structures of CCR5 and CXCR4, both in
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complexes with a small molecular ligand, have been also determined (16, 17). These findings
shed light on the molecular interaction between the envelope and coreceptor. However, because
the viral entry process is highly dynamic and involves large conformational changes of a
complex macromolecular conglomeration, there are still large gaps in our understanding at a
molecular level. The Variable loop 3 (V3) region has been shown to play a critical role in
coreceptor specificity, by making direct contact with the extracellular loops of CCR5 or CXCR4
(18). Regions outside V3 have been found to affect tropism as well, but it is less clear how they
affect the entry process (19-21).
Currently, tropism determination approaches can be broadly categorized as phenotypic or
genotypic approaches. Phenotypic testing, such as the Trofile assay, is primarily based on ex vivo
determination of tropism in established coreceptor expressing cell lines, and has been the gold
standard for tropism determination (22). Recent advances in Next-Generation Sequencing (NGS)
technologies have made genotypic tropism testing more feasible and potentially a cheaper, faster,
and more accurate alternative to phenotypic methods (23-27). The current challenge with the
wide application of genotypic tropism testing lies in the ability to accurately predict tropism
based on amino acid sequences. Current algorithms, such as Geno2Pheno and PSSM, focus
exclusively on the V3 region sequence for tropism prediction; and the outcomes, though accurate
for CXCR4 utilization, have a high false positive rate, and limits the application of CCR5
antagonist drug to patients who could potentially benefit from the therapy (28-30). Therefore, it
is important to better understand the molecular determinants for CXCR4 usage and the structurefunction relationship of HIV-1envelope, thus enhancing the predictive power of the current
methods (20, 31). In addition, new determinants critical for CXCR4 usage can be attractive drug
targets for development of future entry inhibitors.
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Given the challenge that there are a limited number of phenotypically validated envelope
sequences, in which most of the available sequences include only the V3 region, we devised a
novel comprehensive approach that combines phenotypic tropism determination with NGS
technologies, and used it to study a panel of samples from patients who failed a CCR5 inhibitor
clinical trial. By analyzing NGS data of phenotypically validated full-length HIV-1 gp160
sequences, we identified key determinants outside V3 that correlate with coreceptor use and
CCR5 inhibitor resistance.
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3.5 Materials and Methods
3.5.1 Patient samples
HIV-1 envelope amplicons were obtained from participants in a Vicriviroc (VCV) Phase
II clinical trial (AIDS Clinical Trials Group [ACTG] A5211; NCT00082498) (32). Participant
selection and sample preparation were described previously (27). Plasma samples were collected
from study participants who experienced virologic failure and had tropism change by the
phenotypic Trofile assay (Monogram Biosciences). Pelleted virion RNA was used to prepared
env cDNA. Envelope amplicons were generated using previously reported primers (33):
Env1Atopo (5’-CACCGGCTTAGGCATCTCCTATGGCAGGAAGAA-3’)
FLenv2.2 (5’-AGCTGGATCCGTCTCGAGATACTGCTCCCACCC-3’)

3.5.2 Plasmid library generation
Patient envelope amplicons were cloned in frame into HIV-1 molecular clone pNL43.Luc.R–.E– (Dr. Nathaniel Landau, the NIH AIDS Reagent Program) using Gibson Assembly®
Master Mix (New England Biolabs) following the manufacturer’s protocol (34, 35). An AfeI site
(AGCGCT) that does not alter the amino acid sequence was introduced at nucleotide 5954 of
pNL4-3.Luc.R–.E– by site directed mutagenesis. A NotI site is present in the vector at the 4th
codon nef, the position in which the luciferase gene was inserted. The vector was linearized
using AfeI and NotI. The insert was prepared by PCR amplification of the patient envelope
amplicons using the following primers:
NL4-AfeI-EnvF:
(5’-TTGTTTCATGACAAA AGCGCT AGGCATCTCCTATGGCAGGAAG -3’)
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NL4-NotI-EnvR:
(5’- TTTTGGCGTCTTCAGCGGCCGCGCCACCCATCTTATAGCAAAATCCTTTC -3’).
The PCR was set up with Q5 High-Fidelity 2× Master Mix (New England Biolabs) following
manufacturer’s protocol, and run on BioRad T100 thermal cycler (BioRad) using the following
conditions: 98°C for 30 sec; 15 cycles of 98°C for 10 sec, 55°C for 20 sec, and 72°C for 2 min;
and 72°C for 5 min. The PCR product included flanking regions of pNL4-3.Luc.R–.E–. The
Gibson assembly reaction was performed with an insert to vector ratio of 3:1 at 50 °C for 60
minutes. The assembly product was diluted 1:3 and electroporated into ElectroMAXTM Stbl4TM
competent cells (Thermo Fisher) in 1 mm cuvette at 1.2 kV, 25 µF, 200 Ω mA on BioRad
MicroPulserTM (BioRad). Transformants were recovered in 1 mL of S.O.C. medium by shaking
at 30 °C for 90 minutes at 225 RPM, and plated on Luria-Broth agar plates supplemented with
150 g/mL of ampicillin (Sigma-Aldrich).
Plasmid libraries of envelope amplicons were generated by harvesting 106 plate-grown
transformant colonies and extracting plasmid DNA using QIAGEN Plasmid Plus Mega Kit
(Qiagen). Transformed stbl4 cells were plated on 100 mm ampicillin selection plates at 104
colonies per plate. The colonies were incubated at 30 °C for 36 hours before being harvested
using a scraper. The harvested bacterial colonies were centrifuged at 6,000 g at 4 °C for 15
minutes in JA-14 rotor in a J2-HS centrifuge (Beckman). Endotoxin-free plasmid DNA libraries
were prepared according to the Qiagen kit protocol. Plasmid library DNA samples for Illumina
sequencing were prepared by restriction enzyme digestion using NotI and AfeI, followed by
agarose gel purification of the 3 kb band corresponding to the size of the insert envelope gene.
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3.5.3 Cell lines
HEK 293T cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM)
supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, and 1x
antibacterial, antimycotic solution (containing 100 U/mL penicillin, 100 g/mL streptomycin,
and 250 ng/mL amphotericin B). U87.CD4 cells were stably transfected with pBABE-CCR5GFP or pBABE-CXCR5-GFP, constructed as previously described, and maintained in DMEM
supplemented with 15% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 1x
antibacterial, antimycotic solution, 0.2 mg/mL G418, and 1 g/mL puromycin (12).

3.5.4 Virus production and passage
Replication-competent HIV-1 was produced in culture by transfecting 15 g of the
molecular clone plasmid DNA into 4×106 HEK 293T cells using TransIT®-LT1 Transfection
Reagent (Mirus). The viral supernatant was harvested at 48 to 72 hours post transfection and
passed through a 0.44 m syringe filter to remove cell debris. Freshly prepared viral stocks were
passaged on U87.CD4.CCR5 and U87.CD4.CXCR4 cells at low multiplicity of infection (MOI
equal to or less than 0.1), in the presence of 8 g/mL DEAE dextran, as previously described
(12). U87.CD4.CCR5 and U87.CD4.CXCR4 cells were incubated with viral supernatant at 37 °C,
5% CO2, and 95% humidity for 12 hours. After removing the virus and applying fresh media,
infection proceeded for another 24 hours to allow for a single cycle of virus replication. The viral
supernatant was then harvested from the infected U87 cells, number of infectious particles
quantified, and virus then used in the next round of passage.
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3.5.5 HIV-1 luciferase reporter-based titration assay
Viral stocks harvested from 293T or U87 cells were quantified for infectivity on
U87.CD4.CCR5 and U87.CD4.CXCR4 cells using serial dilutions in culture media from 5 to 510
-fold (36). The diluted viral stocks were used to infect 104 U87 cells in 6 replicates in a 96-well
plate in the presence of 8 g/mL of DEAE dextran. Infection was carried out by incubating the
cells with dilutions of viral stocks for 12 hours, removing the virus, and incubating for another
24 hours in fresh media. Cells were harvested 24 hours post-infection and lysed with 0.2%
Triton-X 100 (Sigma-Aldrich) in PBS. The cell lysates were read for luciferase activity on
Optocomp I luminometer (MGM Instruments). A result was scored as positive if the relative
light unit readout was more than 2 standard deviations over the mean of mock infected control
wells. The number of positive and negative wells were counted, and used to compute tissue
culture infectious units using the Spearman-Karber formula.

3.5.6 Functional library DNA preparation
Functional libraries were prepared by PCR amplification of the envelope gene from
integrated proviral DNA using genomic DNA of infected U87.CD4.CCR5 and
U87.CD4.CXCR4 cells, harvested 24 hours post infection using the DNeasy Blood & Tissue
Kits (Qiagen) according to the manufacturer’s protocol for nucleated cells. To include maximum
number of quasispecies and to minimize PCR introduced founder effects, the entire genomic
DNA preparation was used in multiple independent PCR runs using NL4-AfeI-EnvF and NL4NotI-EnvR primers, and the resultant PCR products were pooled. To minimize amplification bias
introduced by varying template copy number, between 400-500 ng of genomic DNA was used as
PCR template for each run, resulting in approximately 6,000 copies of proviral genome per
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reaction, after adjusting for MOI and cell number. The final pooled PCR products were purified
on agarose gels and quantified on TAKE3 plates using Synergy H4 Hybrid Multi-Mode
Microplate Reader (Bio-Tek).

3.5.7 Next generation sequencing (NGS)
DNA samples were submitted to McDonnell Genome Institute at Washington University
in St. Louis, MO for library construction and sequencing using HiSeq 2000 and/or Pacific
Biosciences (Pac Bio) RS II. For amplicon and plasmid library sequencing with Illumina
HiSeq2000, a minimum of 100 ng DNA per sample was used for library construction. The yield
and size of input DNA was determined by a HS Qubit assay for quantitation (Invitrogen) and run
on an Agilent Bioanalyzer 2100 (Agilent Technologies). Small insert dual indexed Illumina
paired end libraries were constructed with the KAPA LTP Library Prep kit (KAPA
Biosystems). 100ng of genomic DNA was fragmented using the Covaris LE220 DNA Sonicator
(Covaris) to a size range between 200-800bp using the following settings: volume = 50µL,
temperature = 4°C, duty factor = 15%, peak incident power = 450, cycle burst = 200, time = 130
seconds. The Illumina ligations were amplified in eight 50uL reactions and were amplified with
10 PCR cycles. Libraries were fractionated on the LabChip XT using the DNA 750 chip (Perkin
Elmer) collecting a 575bp fraction with a +/- 5% covariance, followed by an AMPure XP bead
purification to remove residual small fragments. Each fraction/library was assessed for
concentration and size to determine molarity using the HS Qubit assay and the Agilent
BioAnalyzer High Sensitivity DNA Assay. The concentration of each library fraction was
verified through qPCR according to the manufacturer's protocol (Kapa Biosystems) to produce
cluster counts appropriate for the Illumina HiSeq2000 platform. The libraries were pooled in
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equal molar ratios and loaded on 1 lane of the HiSeq2000 platform utilizing a 2x101bp recipe
according to the manufacturer's recommendations (Illumina).
Functional libraries of 3 kb in length were sequenced with HiSeq2000 as well as Pac Bio
RS II. A minimum of 2 g of functional library env PCR product per sample was submitted for
Pac Bio library construction using SMRTBellTM Template Preparation Kit (Pacific Biosciences)
following the manufacturer’s protocol. Library construction input was 750ng per library. Each
sample was run on a single SMRT cell on the PacBio RS II platform using P6v2/C4 chemistry
and 240 minute movie length.

3.5.8 NGS data analysis
Illumina datasets were quality controlled by performing adaptor trimming, quality
trimming, complexity screening, and length filtering using in-house codes. The amplicon and
plasmid library Illumina datasets were mapped, using BWA (37) or Bowtie2 (38), to samplespecific full-length reference sequences, which were pre-determined by Sanger-sequencing of
single clones. Pac Bio datasets of the functional libraries were quality trimmed using the SMRT
Portal system to extract the high-quality Reads-of-Inserts (ROIs). The ROIs were aligned to
sample-specific references using BWA-MEM. Reads that span the entire V3 region were
extracted and numerated, assuming every individual read represents a single DNA molecule in
the sequencing process. Rare sequences that were occurring at single-digit read level, visibly
different from V3 and likely arising from mapping error and frame-shift translation were
manually removed. Single Nucleotide Polymorphism (SNP) analysis was performed using
GATK Haplotype Caller (https://www.broadinstitute.org/gatk/).
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3.5.9 Phylogenetic and statistical analysis
Hierarchical clustering was performed based on Euclidean distance matrices and
visualized using GENE-E (http://www.broadinstitute.org/cancer/software/GENE-E/) or iTOF
(http://itol.embl.de/). V3 loop consensus sequences from two functional clusterings and their
significantly different amino acid positions were computed and visualized using IceLogo
(http://iomics.ugent.be/icelogoserver/index.html). The statistical significance of the differences
in entropy at every nucleotide position between two samples were determined by Student’s t-test.

3.5.10 Deep Sequence Data Sets
Raw sequence files from this study will be deposited in NCBI Sequence Read Archive (SRA)
upon manuscript acceptance. Accession numbers is TBD.
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3.6 Results
3.6.1 Evaluation of HIV-1 patient samples by deep sequencing
HIV-1 patient samples were collected from eight study subjects at two time points on
ACTG A5211 Phase II study of vicriviroc (VCV) (Table 1). Based on the original Tropile in
vitro phenotypic assay, most study participants (all but Subject 3 and 6) harbored only R5 viruses
before VCV treatment (Time point 1 at Week 0). At the second time point where the subject
experienced protocol-defined virologic failure (less than 1 log10 decrease of HIV-1 RNA level at
or after Week 16), plasma env amplicons demonstrated the ability to utilize CXCR4 for entry,
and their tropism was designated as dual-mixed (DM). The time elapsed between the first and
second time points varied among the study subjects from 2 to 32 weeks.
To understand HIV-1 env sequence characteristics with respect to their function, we
devised a novel experimental scheme that allowed high-throughput phenotypic tropism
determination followed by deep sequencing of functionally validated env libraries (Fig 1A). By
generating a heterogeneous library of replication competent HIV-1 virions that contained a
diverse set of env quasispecies from patient samples, we physically separated the env
quasispecies based on their tropism by passaging the virus on CCR5- or CXCR4-expressing
U87.CD4 cells. The subset of env variants extracted from the proviral DNA in the infected
CCR5- or CXCR4-expressing cells was termed a functional library, and their sequences were
determined on both Illumina and PacBio platforms. To confirm that the sequence heterogeneity
was not lost during the process of molecular cloning, we analyzed the original patient amplicon
samples (named amplicon libraries) and the intermediate plasmid library containing one million
colonies using Illumina sequencing.
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A clustering analysis using single nucleotide polymorphism (SNP) information of the
sixteen amplicon libraries positioned the pair of samples from each study subject on a single
branch of a Euclidean-distance tree (Fig 1B). The clustering pattern was consistent with the
known sample identities, and confirmed that deep sequencing data can be used to accurately
categorize HIV-1 env samples based on their sequence signatures.

3.6.2 Sequence diversity of patient amplicon libraries over time
We first analyzed the Variable loop 3 (V3) coding sequence, as it is the primary
determinant of coreceptor use. We found the patient samples were diverse and heterogeneous, to
a similar degree as previous studies had reported, by counting the number and frequencies of
different variants in the sample (24, 27). An in-depth population level variant analysis was
performed by extracting and enumerating reads that span the entire 33 codons between the two
cysteine residues at the beginning and the end of V3. The assumption was that one read comes
from one DNA molecule, which comes from one quasispecies in the infected individual. Thus,
by enumerating the non-redundant reads, we captured a snapshot of the quasispecies landscape in
the patient at the time of sampling (27). To control for PCR introduced mutations and sequence
errors, we performed PCR amplification and deep sequencing of a clonal control env (data not
shown). We detected 233 distinct non-redundant variants out of 31,989 extracted V3 reads, with
the most abundant variant that was identical to the pre-determined sequence occurring 30,967
times (96.8%). None of the remaining 232 variants exceeded 0.05% of the total population.
Therefore, we concluded that the error rate was low and applied a cut-off filter at 0.05% level to
the sixteen amplicon library datasets to remove possible artifact reads.
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From the sixteen samples coming from eight study subjects, we selected four samples
from two subjects (Samples 1 and 2, Table 1) for the population level variant analysis (Figure 2).
We chose to focus on these two subjects because their samples demonstrated different lengths of
time for coreceptor shift. Subject 1 showed high R5-tropic viral activity at baseline and
comparable R5- and X4-tropic activity in only two weeks, whereas samples from Subject 2
remained predominantly R5-tropic at Week 0 and Week 8, but also showed significantly
increased X4-tropism at the second time point, based on the luciferase assay readings (Table 1).
Examination of the variant profile revealed distinct quasispecies compositions in these two
subjects (Figure 2A-D).
The viral population in Subject 1 before VCV treatment existed as one dominant variant
that accounted for 62.6% of the total population (Figure 2A Variant 1), a less dominant variant at
17.2% level (Figure 2A Variant 2), and numerous rare variants that occurred in single-digit
counts and less than 1% of all V3 reads. On the other hand, the second time point sample (1.2)
contained 2 major variants, at 46.1% and 38.8% abundance, respectively (Figure 2B Variant 1
and 2), followed by a minor variant at 1.4% level, and rare variants at less than 1% level.
Contrary to previous studies and our expectation that a pre-existing CXCR4-using variant at
Week 0 expanded under drug selection to become a major variant at Week 2, we did not detect
the major variants from Sample 1.2 (Figure 2B Variant 1 and 2) in Sample 1.1. Instead, a
completely different and CXCR4-using population emerged and rapidly took over in two weeks,
resulting in escape to the VCV therapy and virologic failure in Subject 1.
Different from Subject 1, Subject 2 showed dynamic expansion and contraction of
variants over the 8 weeks of VCV treatment. At Week 0, the subject harbored multiple major
variants, each at 47.6%, 20.6%, and 8.1% of the total, respectively (Figure 2C Variant 1-3), all of
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which were predicted to use CCR5 exclusively for viral entry based on the Geno2Pheno[coreceptor]
predictive algorithm. Some minor R5-tropic variants from Sample 2.1, present at abundances of
5.9%, 4.7% and 1.4% (Figure 2C Variant 4-6), respectively, persisted and expanded through the
treatment and were detected again at Week 8 at relative abundances of 15.7%, 20.9%, and 9.9%
(Figure 2D Variant 3, 2, and 4). The most abundant variant in Sample 2.2, accounting for 25.7%
of total reads (Figure 2D Variant 1), arose from a rare variant at 0.47% level in Sample 2.1. In
contrast, the two most abundant variants present at 47.6% and 20.6% frequency in Sample 2.1
were completely eliminated from the circulation. Overall, Subject 2 largely retained its
population diversity over 8 weeks, with expansion of pre-existing CXCR4-using variants and
maintenance of several CCR5-only variants in face of VCV treatment.

3.6.3 Evaluation of plasmid and functional library variants
To phenotypically test a large number of env quasispecies, we generated plasmid libraries
of complete NL4.3.Luc+ molecular clones containing env sequences from the two samples of
Subject 1. The plasmid libraries were sequenced with Illumina HiSeq to ensure that the original
quasispecies diversity was retained by the cloning process. We conducted the population level
variant analysis on the plasmid library sequencing datasets and discovered almost identical
variant distributions, with a maximal change of major variant abundance at 3.3% of the total V3
reads (Figure 2E compared to 2A, 2F compared to 2B, and 2G).
Functional libraries were generated by passaging plasmid libraries 1.1 and 1.2, through
U87.CD4.CCR5 or U87.CD4.CXCR4 cells at low MOI (≤0.1) for two or three passages each
consisting of a single-cycle infection. A function library control was also generating by passage
of the single env control in parallel. The four functional libraries obtained through this procedure
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included two independent passages of Sample 1.1 on CCR5-expressing cells (thus named
1.1_R5_FL1 and 1.1_R5_FL2), passage of Sample 1.2 on CXCR4-expressing cells (named
1.2_X4_FL), and a control passage of the single clone isolate from Sample 1.2 on CXCR4expressing cells (named 1.2_Ctrl_X4). The functional libraries were sequenced by PacBio RSII
in addition to Illumina, so that the linkage information between SNPs longer than 100 bases apart
could be studied.
High-quality Reads-of-Inserts (ROIs) of the 4 functional libraries from the PacBio
platform were generated. A total of 26,046 ROIs were obtained passed a quality filter of 99% per
base accuracy, including 4667 ROIs from 1.1_R5_FL1, 8707 ROIs from 1.1_R5_FL2, 6783
ROIs from 1.2_X4_FL, and 5889 ROIs from 1.2_Ctrl_X4. The average length for ROIs is 2260
bp, with the majority of ROI at 2.9 kb, consistent with the input fragment size. All ROIs were
generated from circular consensus sequencing of 10 passes or more, resulting in low error rate
per base and high quality output sequencing reads.
Analysis of variants at population level in the four functional libraries was performed to
understand the quasispecies profile across the envelope variable regions (Figure 3). Insufficient
reads from the V1 region were extracted to permit meaningful analysis, likely due to the
incompatibility between our stringent read extraction criteria and the presence of large insertion
and deletions in this region. Therefore, we focused on the V2 through V5 regions instead. To
control for the errors introduced by PCR, virus passaging, and sequencing procedures, we
analyzed the clonal control 1.2_Ctrl_X4 functional library at V2 through V5, and detected
minimal amounts of deviant variants across the five regions (data not shown). Overall, in the
three remaining libraries, the analysis revealed distinct quasispecies landscapes for R5 versus X4
variants. The two biological replicates, 1.1_R5_FL1 and 1.1_R5_FL2, were highly consistent in
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terms of the major variants and their abundances across V3 – V5 regions, confirming that the
passaging method was a reliable and reproducible approach to capture functionally validated
quasispecies (Figure 3, Columns 1 and 2). Comparing the variant composition across the variable
regions, the variants from V2 through V4 were more closely correlated, consistent with one
major and one minor clone in 1.1_R5_FL1 and FL2, and two major clones in 1.2_X4_FL1. The
V5 region appeared more variable in R5-using populations than in X4-using populations, and
showed less correlation with the other three regions.
Examination of the quasispecies profiles in the V3 region of the functional libraries show
that they were highly similar to those of the starting amplicon libraries (Figure 2A-B, Figure 3).
The most abundant variants in Sample 1.1 and 1.2 amplicon libraries were present in the
functional libraries, suggesting the V3 variants observed in the amplicon libraries were part of
full-length, functional env quasispecies. The two most abundant variants in Sample 1.1 (Figure
2A Variant 1 and 2), as well as the three most abundant variants in Sample 1.2 (Figure 2B
Variant 1-3) were detected at comparable proportions in the functional libraries (Figure 3, Row
2). Interestingly, a rare variant in the original amplicon library of Sample 1.1 at only 0.13% level
(Figure 2A and B) expanded through the passaging to become the third most abundant variant in
1.1_R5_FL1 at 3.5%, and the second most abundant variant in 1.1_R5_FL2 at 7.1% (Figure 3,
Row 2). This suggested that the enrichment and contraction of variants in the functional library
were not stochastic events. The ability of certain variants but not the others to persist through the
passaging process was directly dependent on their capacity to facilitate cell entry using CD4 and
one of the two coreceptors at a given CD4 and coreceptor concentration of the reporter cell lines.
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3.6.4 Characterization of V3 variants based on sequence signature shows consistency with
functional tropism
To dissect the sequence signature of HIV-1 env isolates and its relationship with the
coreceptor binding function, we generated a hierarchical cluster, based on a Euclidean-distance
matrix, using 167 V3 variants from all 4 functional libraries (Figure 4). The sequence-based
clustering separated the variants into two groups that coincided almost perfectly with their
function, except for three variants from CCR5 functional libraries that were grouped with
variants from CXCR4 libraries (Figure 4, circled in green). These three variants were predicted
by the Geno2Pheno algorithm to be able to also use CXCR4 for entry, suggesting that these were
rare variants before treatment that could utilize CXCR4 for entry but did not expand upon VCV
treatment likely due to low fitness.
We generated consensus sequences of all the variants in each cluster with IceLogo2,
taking into consideration their respectively abundance, and identified amino acid positions
differentiating cluster 1 and cluster 2 at a significance level of P < 0.001 (Figure 5). The variants
in CCR5 functional libraries were highly similar to each other based on the Logo plots, and were
distinct from those in CXCR4 functional libraries. Cluster 1 showed a high degree of
conservation, which was reflected by a major variant that accounted for over 80% of the
population. Cluster 2 showed a clear divergence at Position 31, which was representative of two
major variants at 43.5% and 50.2%, respectively (Figure 5A). Altogether, we identified nine
positions (Positions 2, 20, 22, 23, 24, 25, 31, 32, and 34) in the V3 region with significantly
different amino acid residues, that were likely responsible for the differential functionality to
engage CCR5 versus CXCR4 as entry coreceptor (Figure 5B). Consistent with our observation,
these positions and amino acid residues have been previously reported in HIV-1 Subtype B and
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C patient samples to correlate with CCR5 or dual-tropism (39, 40). In addition, at the 25th
position in Cluster 1 was a negatively charged glutamic acid, whereas occupying the same
position in Cluster 2 was a positively charged lysine, which was indicative of CXCR4-usage by
the 11/25 Rule (41). Through the clustering and consensus analysis, we demonstrated that
categorizing HIV-1 V3 variants by sequence similarity created clusters that were consistent with
their function, and confirmed that the V3 region is a critical modality for coreceptor tropism
determination.

3.6.5 Important regions outside V3 that correlate with envelope tropism
We analyzed the full env gene to examine other determinants of tropism beyond the V3
region using Shannon’s entropy approach and SNP analysis. Shannon’s entropy analysis
examines cross-sectional diversity at a given position, with higher entropy values responding to
more diversity. We utilized entropy analysis to compare the entropy values at each nucleotide
position between amplicon libraries of Sample 1.1 and 1.2 to explore regions that were
undergoing an increase or decrease in diversity due to VCV selection.
Overall, Sample 1.1 had higher entropy across the length of the env gene than Sample 1.2,
as demonstrated by 120 positions in Sample 1.1 and only 50 positions in Sample 1.2 that have
statistically above-background entropy values when compared with the clonal control dataset
(Figure 6A, p<0.0001). This suggested that the viral quasispecies population before VCV
treatment was more heterogeneous than the quasispecies present after treatment. The treatment
likely selected for a dominant drug-resistant variant, or a group of closely related resistant
variants, thus, driving down the overall diversity in the population. The decrease in entropy from
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1.1 to 1.2 occurred mostly in the V1, C2, and C5 regions, as represented by the entropy
difference map (Figure 6B). However, specific locations showed an increase in entropy, in
particular at HR1/HR2 regions and the cytoplasmic domain of gp41, suggesting diversifying
selection at those loci (Table 2).
SNP analysis on the four functional library datasets using GATK program identified 106
SNPs in the entire env gene with reference to the control single clone sequence from Sample 1.2.
Clustering of the four functional library datasets based on their SNP frequency patterns reflects
the functional categorization of the four libraries, with 1.1_R5_FL1 and 1.1_R5_FL2 on a single
branch, and away from 1.2_X4_FL and 1.2_Ctrl_X4 on a different branch (Figure 7A). To
identify SNPs that could differentiate CCR5 versus CXCR4 coreceptor usage, we focused on 23
non-synonymous loci (annotated in the red boxes) that were completely different in CCR5-using
groups than in CXCR4-using groups, including 22 loci outside the V3 region. Among the 23
positions identified, 4 positions (N325, K421, I424, and S440) were previously known to
strongly affect coreceptor binding and specificity, and 3 positions (N425, K432, and R476) were
reported to be CD4 binding residues (13, 42, 43). Sixteen positions identified through the SNP
analysis have not previously been identified to have a function in receptor or coreceptor binding,
although many were found to be involved with gp120 – gp41 interaction (Table 2) (42-45). This
finding suggests a role of gp120-gp41 interaction in coreceptor specificity, potentially by
affecting entry dynamics and thus fusion efficiency following coreceptor binding.
For visualization of the critical regions that correlated with coreceptor specificity,
annotation was performed on the ligand-free native envelope gp140 trimer crystal structure (PDB
ID: 4MJZ) (Figure 7B and 7C). A group of residues (colored red) that were previously reported
to be coreceptor-specific is located near the envelope-coreceptor binding interface and likely to
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affect binding via direct contact with extracellular regions of the coreceptors. A second group of
residues (colored magenta) located near the CD4 binding site are likely to affect coreceptor
usage via interaction with CD4 and subsequent induction of a conformational change into an
open trimer. A third group (colored blue and green) that is located at gp120-gp41 contact
interface and the interface between the three subunits is likely to affect tropism via global
mechanisms, such as alteration of the overall configuration of envelope trimer or its dynamic
conformation change upon CD4 and/or coreceptor engagement.
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3.7 Discussion
In this study, we developed a comprehensive phenotypic assay platform in combination
with NGS technologies to analyze HIV-1 quasispecies diversity and tropism before and after
emergence of drug resistance in vivo. This novel approach employed a tissue-culture based
library passaging method and allowed us to study in unprecedented depth and breadth the
quasispecies population and their structure-function relationship by generating sequences from
phenotypically validated env variants. The output data provided new insights into important
features of HIV-1 env that are implicated in coreceptor interaction, and could shed light on new
drug targets for HIV-1 entry inhibitor development. In addition, the experimental approach can
potentially be adapted for the study of drug resistance development in other clinical situations,
especially for development of unusual combinations of drug resistant mutations that requires
phenotypic characterization of new and complex genotypes.
Quality control of the sequencing data is extremely important in NGS-based studies to
ensure the accuracy and relevance of the final conclusion. In our study, we performed all the
experimental procedures including PCR, cloning, infection, passaging, Illumina and PacBio
sequencing, reads filtering, and the final analysis with a clonal control of known nucleotide
sequence in parallel. Therefore, we could calculate the cumulative error rate of PCR and cloning
errors, passaging artifacts, and sequencing errors at every step of the process by analyzing the
single clone control dataset and apply an appropriate filter level based on the control error rate.
Notably, the combined error rate from PCR and sequencing in our experience were markedly
lower than previously reported, likely reflecting improved accuracy of the higher-fidelity PCR
polymerase and of the newer generation sequencing method (27). A potential source of error that
we could not control for using the single clone method is strand-switching (recombination)
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during the PCR process. Based on previously published information, the recombined clones
accounted for equal to or less than 0.15% in the total population, and did not significantly affect
the proportions of truly existing variants (27). In addition, we also utilized the amplicon and
plasmid library dataset as baseline for the functional library variant analysis, and removed
variants that did not exist in the first two libraries, therefore eliminating the majority of
recombination errors and passaging artifacts. Biological replicates of Sample1.1 on CCR5expressing cell lines served as another layer of control and confirmed that our approach is robust
and reproducible.
The quasispecies landscape at the two snapshots through time in two study subjects
alluded to different evolutionary pathways. Through analysis of V3 variants in amplicon libraries
from Subject 1, we were unable to detect a minor variant at Week 0 that expanded into a major
variant at Week 2 despite multiple rounds of sequencing and extensive depths of coverage at
600× to 6000×. Though a minute possibility remains that the major CXCR4-using variants in 1.2
were present in1.1 at a level too low to allow detection, a more plausible hypothesis is that the
virus had undergone de novo mutations that conferred CXCR4-utilization, and achieved a
complete population shift and coreceptor switch within 2 weeks. Consistent with the “fitness
valley” model of coreceptor shift, we detected few intermediate variants from CCR5-only to
CXCR4-using genotypes, as they are thought to be less fit and are quickly selected out (46, 47).
On the contrary, Subject 2 demonstrated a typical dynamic quasispecies population shift under
the selection pressure from the CCR5 antagonist, during which rare pre-existing CXCR4-using
clones expanded and susceptible clones declined. Interestingly, several major variants predicted
to be R5-tropic only in Sample 2.1 had unexpectedly persisted and expanded over treatment,
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perhaps by acquiring resistance through an alternative mechanism, such as binding to the CCR5VCV complex for entry (6).
One limitation of this study is the sampling method. We were unable to access
quasispecies residing in lymph nodes and latently infected cells, as the patient samples were
collected and prepared from free circulating virions in the plasma. Since HIV-1 quasispecies at
these sanctuary sites are often sheltered from antiretroviral therapy, or are exposed to a lower
dose and sub-optimal combination of antiretroviral drugs, the virus may continue to replicate at
low levels and develop resistance progressively in a step-wise fashion, even when the treatment
appears fully suppressive (48). Some of the viral quasispecies that eventually escape treatment
and migrate to the blood are predicted to harbor multiple mutations, consistent with our
observations. A recent study also shows that proviral populations in peripheral blood
mononuclear cells are different from those in lymphoid organs and in latently infected memory
cells; the variants in circulation are often defective or less fit (49). Since we are just beginning to
understand these tissue-localized HIV quasispecies, more studies are needed to examine the
evolutionary process in local lymphoid tissues and latently infected reservoirs to elucidate how
they contribute to coreceptor shift and resistance development.
Finally, this study has identified three regions outside V3 that strongly associate with
coreceptor shift in the context of VCV selection, including the C4/V4/C5 region, CD4 binding
site, and the interaction surface between gp120-gp41 and between gp41 subunits. A majority of
the residues identified in the first two regions are consistent with and confirm previously
published data on coreceptor specificity and viral entry. In contrast, a new subset of mutations at
the gp120-gp41 interaction site alludes to interesting new possibilities for the mechanism of
coreceptor shift. Since the gp120-gp41 interaction surface is located away from gp120117

coreceptor interaction surface, mutations in this region are unlikely to directly affect gp120
binding to coreceptor by charge or binding surface steric hindrance. They may, however, affect
the trimer conformation and alter the affinity of envelope trimer to one coreceptor versus the
other. These mutations may also compensate for the decrease of viral fitness from changes in
other regions of env and promote viral entry. The new line of evidence demonstrated in this
study contributes to our understanding of the dynamic macromolecular interactions during HIV1 entry, warrants further investigation via mutagenesis studies into the coreceptor shift process,
and potentially sheds light on a new therapeutic target for entry inhibitors.
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3.10 Tables
Table 3.10.1 Longitudinal changes of HIV-1 envelope tropism in VCV treated patients
*Subject ID
1
2
3
4
5
6
7
8

Sample ID
1.1
1.2
2.1
2.2
3.1
3.2
4.1
4.2
5.1
5.2
6.1
6.2
7.1
7.2
8.1
8.2

Time (weeks)
0
2
0
8
0
24
0
32
0
8
0
8
0
8
0
2

R5-RLU** X4-RLU** Tropism***
593008
86
R5
139491
185312
DM
7360
129
R5
6260
2034
DM
774210
388
DM****
223785
1178193
DM
434886
76
R5
6627
117574
DM
37210
66
R5
50461
78889
DM
511349
1920
DM
124983
173363
DM
90578
63
R5
8211
9836
DM
391164
73
R5
1789
151040
DM

* Subject: HIV-1 patients who experienced virological failure (defined as smaller than 1 log10
viral load decrease at or after week 16 by protocol) in a Vicriviroc phase IIb clinical trial.
** RLU: Relative Light Units by luciferase-based Trofile® assay on CCR5 (R5) or CXCR4 (X4)
expressing cell lines.
*** Tropism: the ability of the virus to utilize R5 and/or X4 for viral entry.
**** DM: dual/mixed tropism. Dual tropism: the ability to utilize both R5 and X4 for entry;
mixed tropism: coexistence of viral species that can use either R5 or X4 coreceptor for entry.
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Table 3.10.2 Positions within and outside the V3 region that correlate with coreceptor usage

SP
C1
V1
C2
V3
C3
V4
C4

V5
C5

FP
FPPR

HR1
HR2
CD

Position
*
24
26
29
86
87
134a
240
256
325
327
351
412
421
424
425
432
440
442
444
465d
476
490
496
500
503
514a
518
525
534
535
541
543
555
596
621
633
724
749
802

SNP
+

Entropy
value** p value++
-0.955
5.62E-05
-0.901
2.99E-05
0.988
2.43E-05

L/M
E/G
-0.956
-0.716
-0.757

5.73E-05
1.98E-05
1.38E-05

0.988
-0.714

6.62E-05
6.36E-04

D/N
E/K
E/D
R/K
V/I
N/K
K/T
N/S
S/R
R/K
K/R
Q/K
L/V
K/M

-0.871

3.03E-05

-0.931

8.74E-04

-0.707
-0.918
-0.757

7.71E-05
4.28E-05
5.76E-05

M/T/I
V/M
T/A
A/S
-0.819

4.70E-05

0.495
-0.989
-0.239

7.18E-04
1.23E-05
1.57E-04

0.311
0.983
0.991
-0.498

9.52E-05
6.38E-05
2.72E-05
7.12E-05

T/A
R/Q
E/D

Significance

Citation

gp120-gp41 within one protomer
gp120-gp41 interaction surface within
single protomer; N88 glycosylation

47

Coreceptor binding site within V3
Coreceptor binding site within V3

44

Coreceptor binding site outside V3
Coreceptor specific site (R5X4)
CD4 contact site, main & side chain
CD4 contact site main chain only
Coreceptor binding outside V3; R5/X4
Coreceptor binding site outside V3
Cys 378 linked to Cys 445

44, 13

CD4 contact site, side chain only

45

gp120-gp41 interaction surface within
single protomer; RRE stem I start

46, 47

gp120-gp41 interaction surface within
single protomer
gp41-gp41 interaction site & surface
between two protomers
gp120-gp41 interaction surface within
single protomer

47

gp120-gp41 interaction surface within
single protomer
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45
44

44, 47

47

* Positions are numbered based on alignment to HXB2.
+

Positions showing > 70% switch from reference to alternative allele in SNP analysis are

annotated as ref/alt/alt. Reference allele is based on 1.2 single clone control sequence.
** Entropy value = entropy value of Sample 1.2 AL – entropy value of Sample 1.1 AL Positive
value: increase in entropy/diversity; negative value: decrease in entropy.
++ Positions with a significant change of entropy have p values <0.0001, by two-tailed t-test
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3.11 Figures
Figure 3.11.1 Experimental design and clustering of 16 samples

(A) Schematic diagram of the experimental design. Patient derived envelope quasispecies
amplicons (amplicon libraries) were cloned into replication competent NL4.3Env-luc+ reporter
vector (plasmid libraries) and expressed in 293T cells as replication competent virions that were
used to infect CCR5 and CXCR4 expressing cell lines. The functionally validated env
quasispecies (functional libraries) were prepared by polymerase-chain reaction of the proviral
DNA using env-specific primers from the genomic DNA of the infected cells. The three sets of
libraries were sequenced by Illumina HiSeq2000; functional libraries were also sequenced by
Pacific Biosciences RS II. (B) SNP based clustering analysis of 16 amplicon libraries based on
Illumina sequencing of the full-length env gene. SNPs were called with HXB2 env as the
reference sequence using GATK. A Euclidean-distance based clustering of 16 amplicon libraries
was constructed using 843 SNPs present in all samples.
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Figure 3.11.2 Population analysis of V3 loop sequences and frequencies in amplicon and
plasmid libraries.
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(A) Sample 1.1 amplicon library (AL), (B) Sample 1.2 AL, (C) Sample 2.1 AL, (D) Sample 2.2
AL, (E) Sample 1.1 plasmid library (PL), and (F) Sample 1.2 PL. (G) A summary table
compares amplicon libraries versus plasmid libraries for Sample 1.1 and 1.2. Total V3 reads are
representative of the depth of sequencing. A clonal control env from Sample 1.2 was prepared
and sequenced in parallel. For amplicon and plasmid libraries in (A) – (F), unique V3 variants
and their respective frequencies are represented as slices on a pie chart. The same color in
different libraries represents a common V3 variant found in both libraries. For amplicon libraries
in (A) – (D), the sequences and proportions of the most abundant V3 loop variants are listed. The
coreceptor usage predicted by Geno2Pheno[corecptor] is shown for every sequence. The
significance level of the prediction was set at 2% and 5.75% False-Positive Rate (FPR) as the
optimized cut-offs based on clinical data from the MOTIVATE study (FPR<0.2%: X4-capable;
th

FPR>5.75%, X4-incapable.) *For the 5 most abundant variant in Sample 2.2, the V3 sequence
is predicted to be X4-capable with a FPR of 5.4%, which falls in between the optimized cut-off
values.
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Figure 3.11.3 Functional library population level variant analysis at env variable regions.

Reads extracted from variable regions V2 (HXB2 gp160 amino acid 158 – 186d), V3 (297 –
330), V4 (385 – 418) and V5 (460 – 469) from functional libraries 1.1_R5_FL1, 1.1_R5_FL2,
and 1.2_X4_FL1 are visualized in pie charts with the most abundant variants annotated.
1.1_R5_FL1 and 1.1_R5_FL2 are biological replicates prepared from Sample 1.1 passaged on
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U87.CD4.CCR5 cells. 1.2_X4_FL1 was prepared from Sample 1.2 passaged on
U87.CD4.CXCR4 cells. Sequencing data shown were generated on the PacBio RS II system.
Individual reads that span through the entire region between the given coordinates were selected,
trimmed, and translated into amino acid sequences. Quasispecies are represented by nonredundant amino acid sequences and are color-coded across libraries in the same row. V3
variants are represented in same colors in Row 2 as in Figure 2A-B, and E-F.
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Figure 3.11.4 Hierarchical clustering analysis of 167 V3 variants from four functional
libraries (1.1_R5_FL1, 1.1_R5_FL2, 1.2_X4_FL1, and 1.2_Ctrl_X4).

Cluster 1

82.8% of 1.1_R5_FL1
83.2% of 1.1_R5_FL2
a
b
c

50.6% of 1.2_X4_FL1

1.1_R5_FL1
1.1_R5_FL2

43.5% of 1.2_X4_FL1
99.1% of 1.2_Ctrl_X4

1.2_X4_FL1
1.2_Ctrl_X4

Cluster 2

The presence and absence of variants is indicated using the color coded squares. Highly
abundant variants are indicated by arrows. Green circles denote variants a, b, and c from
1.1_R5_FL1 and/or 1.1_R5_FL2, which were grouped in Cluster 2 and predicted to use CXCR4
by Geno2Pheno[coreceptor].
Sequences for the three circled variants are:
a – CTRPNNNTRKGIHIGPGRAVYVAEKIIGNIRQAHC;
b – CIRPNNNTRKGIHIGPGRAVYVAEKIIGNIRKAYC;
and c – CTRPNNNTRKGIHIGPGRAVYVAEKIIGNIRKAYC.
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Figure 3.11.5 V3 Logo Plot for Cluster 1 and 2.

A

B

(A) ConsensusV3 sequences of Cluster 1 and 2.
(B) Significantly different amino acids (P < 0.001) between the V3 loop sequences from cluster 1
and cluster 2. Critical residues at the 11th and 25th positions are highlighted with red arrows.
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Figure 3.11.6 Shannon’s entropy analysis of amplicon libraries (AL) from Sample 1.1 and
1.2.

1.8

C1

Shannon's Entropy Index

1.6

V1

V2

1.4 SP

C2

V3

C3

V4

C4

C5 FPPR
FP HR1

V5

1.2

1.1 AL
1.2 AL

HR2

1.0
0.8
0.6
0.4
0.2
0.0

Entropy (1.2 - 1.1)

-0.2

0

1.6
1.4
SP
1.2
1.0
0.8
0.6
0.4
0.2
0.0
-0.2
-0.4
-0.6
-0.8
-1.0
-1.2
-1.4
-1.6
0

500

C1

V1

1000

V2

C2

V3

1500
Position (nt)

C3

V4

C4

1000

2500

C5 FPPR
V5

500

2000

FP HR1

1500
Position (nt)

HR2

2000

2500

(A) Absolute entropy values at each nucleotide position along the env genes for 1.1 AL and 1.2
AL. A total of 120 positions in Sample 1.1 (blue) and 51 positions in Sample 1.2 (red) have
entropy values significantly over background entropy values in the 1.2 clonal control dataset (not
shown), by one-tailed Student’s t-test, p<0.0001.
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(B) Entropy difference at each nucleotide position along the env genes, by subtracting the values
of 1.1 AL from that of 1.2 AL. At 17 positions, the entropy values in Sample 1.1 differ
significantly from those in Sample 1.2, by two-tailed Student’s t-test, p<0.0001.
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Figure 3.11.7 Residues outside the V3 loop differentiate R5- vs. X4- usage.

(A) Clustering analysis based on SNP loci allele frequency of the full-length env in four
functional libraries. A total of 106 SNP loci were identified by GTAK using the nucleotide
sequence of the single clone control (1.2_Ctrl_X4) as reference. The reference allele frequency
at each locus was calculated in every functional library and is represented as a colored block
along the vertical axis of the plot. Euclidean distance based matrix was used to generate the
clustering using GENE-E. The branching over the horizontal axis represents genotype similarity
based on similar patterns of SNPs found in all four samples. A total of 37 differentiating SNPs
are found in the regions outline by the red boxes, among which 24 SNPs lead to nonsynonymous amino acid substitution. Only 1 out of the 24 SNPs falls within the V3 loop region.
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(B) Representation on the gp140 SOSIP ligand-free trimer structure (PDB ID: 4ZMJ) of 21 loci
differentiating CCR5 from CXCR4 utilization. The front view shows a trimeric spike with gp41
on the top and gp120 at the bottom. The bottom view shows the perspective looking up from the
host cell membrane. The subunits are shown in surface model, with gp120 in light grey and gp41
in dark grey in two of the three protomers. The third protomer is colored by region as the
following: light blue, gp41 ectodomain; pink, gp120; pale-yellow, V1/V2 loop; orange, V3 loop;
and magenta, CD4 binding site (CD4bs). The differentiating loci are color-coded based on their
known functional status previously reported in the literature. Red: coreceptor binding or
coreceptor specific site; magenta: CD4 contact residues; blue: intra-protomer gp120-gp41
interaction site; green: inter-protomer gp120-gp41 and gp41-gp41 interaction site; teal: no
previously reported function in receptor or coreceptor interaction. (C) Enlarged front and back
views of the 21 differentiating residues on a cartoon representation of gp140 subunit. The
residues are annotated and grouped based on their functional status and color coded in the same
manner as in (B).
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Discussion and Future Directions
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4.1 Summary
HIV/AIDS remains a significant public health problem worldwide. The cause of this
problem can be attributed to the following three factors. Firstly, the lack of access to diagnostic
testing and counselling in low- and middle-income countries with high disease burden, limited
financial resources, and poor public health infrastructure leads to a high undiagnosed rate and
further spread of the disease. WHO estimated that a large share of HIV-1 infection is
undiagnosed in regions of Western Europe, Eastern Mediterranean, and Sub-Saharan Africa
(WHO). Secondly, the lack of access to transmission prevention measures such as anti-retrovirals
for pregnant HIV-1 positive women to block mother-to-child transmission, clean needles for
intravenous drug users, and condoms to block sexual transmission contributes to the 2 million
annual new infection cases. This is likely due to lack of financial resources, social stigma and
punitive government policy (UNAIDS). Thirdly, the lack of consistent and reliable access to
effective HAART drugs for treatment eligible individuals in low- and middle-income countries
with high HIV/AIDS prevalence continues to bring morbidity and mortality to a
socioeconomically disadvantaged population. The need remains to continue development of lesstoxic, more effective, new classes of antiretroviral agents, and potentially curative agents in
pharmaceutical pipelines to battle issues with the current life-long therapy, such as hepatic and
renal toxicity, and development and circulation of drug-resistant strains.
One such new class of antiretroviral agent is entry inhibitors. These inhibitors work by
blocking viral entry, the first step of the viral replication cycle. HIV entry into a host cell is a
dynamic, multi-step process that involves viral attachment to the host cell extracellular matrix or
receptor, viral envelope protein engagement with primary receptor CD4, recruitment and
engagement of one of the two coreceptors CCR5 and CXCR4, followed by eventual formation of
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the six-helix bundle and fusion pore, and translocation of viral nucleocapsid core into the host
cell cytoplasm, as discussed in the first chapter of this dissertation. Every step in this process is
being targeted for the development of novel entry inhibitors. Currently, two FDA-approved entry
inhibitors include Enfuvertide (Fuzeon, Roche) that competitively blocks six-helix bundle
formation and fusion, as well as Maraviroc (Selzentry, Pfizer) that is an allosteric inhibitor of
CCR5 and blocks envelope-CCR5 interaction. A number of other small molecule inhibitors and
monoclonal antibody based biologics are being developed through preclinical and clinical phases,
among which are several coreceptor antagonists, notably CCR5 antagonists Vicriviroc (VCV)
and TAK779, and a potent CXCR4 inhibitor AMD3100 which are not approved for HIV-1
indication due to its side effects. During the development process and clinical application of
some of these coreceptor inhibitors, the outgrowth of resistant strains were detected in patients
despite tropism testing prior to treatment commencement. Multiple mechanisms were found to
be responsible for resistance development, including a tropism change of the virus from CCR5 to
CXCR4, and a gain in the ability of the virus to engage the CCR5-antagonist complex for entry.
The former mechanism of coreceptor shift represents the majority of CCR5-antagonist resistant
cases, and could be further broken down into two pathways, including (1) selective expansion of
a minor, pre-existing CXCR4-tropic viral variant that is not detected by tropism testing, under
the drug pressure; and (2) de novo mutations of the virus to gain the ability to utilize CXCR4 as
its entry coreceptor. A thorough understanding of the coreceptor shift process and the route it
takes would help with the development of more suitable clinical criteria for CCR5 antagonist
eligibility, and with the design of more effective treatment plans in order to minimize resistance
development and provide benefit to the largest possible population of eligible patients.
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This study utilized a panel of patient-derived HIV-1 envelope amplicon samples before
and after the development of VCV resistance in order to advance our understanding of the
coreceptor shift process in vivo, as well as the basic biology of envelope-coreceptor interaction in
general. Using a combination of single clone and next-generation sequencing (NGS) approaches
discussed in Chapter 2 and 3, we characterized a large number of clinical isolates of HIV-1
VCV-resistant envelope, and examined in-depth the quasispecies landscape in these patients
before and after they became resistant to VCV treatment. We discovered drastic changes in
envelope sequences over the course of treatment from the single clone analysis, and observed
dynamic quasispecies population shift over the course of 2-8 weeks by NGS. With an array of
phenotypic and genotypic assays, we analyzed a large batch of phenotypically validated
envelope sequences, and with the Pacific Biosciences technology we were able to study
mutations occurring along the full-length gp160 coding sequence. We detected three regions of
interests that strongly associate with CXCR4-usage, including but not limited to the V3 loop,
which is the principal determinant of coreceptor specificity supported by a large body of research.
We identified important residues that were (1) previously reported to play a role in coreceptor
choice within and surrounding to the V3 loop; (2) reported to be CD4 contact residues, and (3)
located on the gp120-gp41 interaction surface within one gp160 heterodimer and between the
neighboring heterodimers within an envelope trimer spike. In addition to confirming previous
finding that residues in the V3 loop and CD4 binding site, which make direct contact with
coreceptor and CD4, affect coreceptor specificity, we provided new evidence that the interaction
between gp120 and gp41, as well as the interaction between the heterodimers in an envelope
spike, could modulate coreceptor binding. This new line of evidence leads to new hypothesis that
the envelope protein interaction with coreceptor could be influenced possibly through more
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global mechanisms, such as the open or closed state of envelope quaternary structure, stability of
a particular conformational state that allows for coreceptor binding, and the affinity and duration
of coreceptor engagement that leads to fusion and viral entry.
Understanding of the structure-function relationship of HIV-1 envelope and the process
of coreceptor shift is critically important, not only for the advancement in our basic scientific
knowledge of protein-protein interaction, but also with profound clinical implications in
development of diagnostic methods and future pharmaceutical agents. The findings from this in
vivo study provides candidates for further in vitro causative study on envelope structure-function
relationship, as well as potential ways to improve the current tropism predictive algorithms by
incorporating residues with differentiating power for CXCR4-usage. It also provides new
thoughts along the lines of modulating gp120-gp41 interaction via small molecules or
monoclonal antibodies to restrict its quaternary structure as an approach to block entry. Last but
not least, the knowledge of specific envelope-CXCR4 interaction sites in combination with
known interaction sites between CXCR4 and CXCL12 could potentially lead to design of
specific inhibitors that preferentially block envelope binding to CXCR4 but do not interfere with
the physiological CXCR4 signaling that is essential for immune function. Further investigations
are needed in the above mentioned areas to impact HIV/AIDS diagnosis, monitoring and
treatment options.
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4.2 Discussion
One of the major strengths of this study is that we were able to observe the viral
quasispecies evolutionary process in vivo. The in vivo nature of study design allowed us to make
conclusions that are based on physiological processes occurring in their natural environment.
The patient samples were paired and contained before and after treatment samples for each study
participant. Our assumption is that factors shaping the immune environment, including but not
limited to cytotoxic T lymphocyte (CTL) and antibody responses, as well as the specific genetic
makeup such as HLA, CD4, and coreceptor genotype, remained largely constant throughout the
course of treatment; thus the major variable and driving force for coreceptor shift is the
introduction of CCR5 antagonist into the system. The evolutionary process of coreceptor shift
was primarily driven by VCV, with important constraints from the above-mentioned specific
immune and genetic environment that is mostly lost in many in vitro evolutionary studies.
Without the CTL and antibody responses and in the presence of non-physiological levels of CD4
and coreceptor expression, the mutations detected in an in vitro drug resistance development
setting often bear no resemblance to the ones seen in patients. In fact, over the three passages of
viral quasispecies in the process to generate functional libraries as described in Chapter 3, we
detected a small group of V3 variants in Sample 1.2 that lost the GPG crown motif and deviated
significantly from the input sequences. With proper quality controls based on the quasispecies
pool in the amplicon and plasmid libraries, we were able to manually remove these artefactual
variants that could potentially affect downstream analysis. This highlights the necessity of
studying the evolutionary process in a controlled, physiological setting to avoid erroneous and
irrelevant conclusions.
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The flip-side of the story for an in vivo study is that it is difficult to determine causation
in the structure-function relationship analysis. The conclusions were based on a strong
association between certain specific residue changes and the utilization of CXCR4, yet it is
unclear on the differentiation of key driver mutation versus auxiliary mutations. Further in vitro
site-directed mutagenesis studies are required to understand the effect of one mutation or a
combination of mutations on envelope-coreceptor interaction. Identifying key residues in
multiple patients would also strongly indicate a causative role of these particular loci in
coreceptor shift. With the availability of the remaining six patient-derived envelope amplicon
samples, we certainly hope to continue examine the coreceptor shift process in more patients, to
increase the power of the analysis and understand the findings in a broader context that are
applicable to multiple patients.
One limitation of this study comes from the sample collection methods utilized. Since the
patient-derived envelope amplicon samples were prepared from patient plasma, we are limited to
exam the quasispecies population in circulation and do not have access to those variants residing
in the peripheral lymphoid organs or the latently infected reservoirs. A recent study showed that
the clonally expanded T cells in the circulation are more likely to harbor defective provirus
containing deleterious mutations and large deletions than the quiescent non-dividing latently
infected memory T cells, which usually harbor replication competent proviruses (1). This report
is consistent with our observation that a large proportion of the single clones are non-functional,
though molecular cloning artifact would also have a minor contribution towards the detection of
non-functional single clones. On the other hand, previous reports have discussed the
development of drug resistant variants in local tissues due to imperfect penetration and the
mismatched half-lives of antiretroviral agents (2). Viral quasispecies in the local tissue may be
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sheltered from full-strength HAART, and make slow, step-wise mutation in the context of the
microenvironment of temporal and spatial monotherapy, only “spilling over” into the circulation
upon achieving full drug resistance. This is consistent with our observation that the quasispecies
population underwent a complete change of constituents over the course of treatment, and few
drug-resistant intermediate variants were detected. This observation could be due to insufficient
resolution and limits of detection to reveal rare, low-fitness variants in the circulation.
Alternatively, it might be because we were looking in the wrong place, and should examine the
quasispecies pool at the peripheral tissue instead. Future research should be conducted with the
help of powerful NGS technologies to closely analyze viral quasispecies population in the latent
reservoir and the peripheral tissues such as the central nervous system, in the hope to complete
the missing pieces in the evolutionary pathway.
Overall, this study made a significant contribution to our knowledge of HIV-1 envelope
structure-function relationship. The findings suggest a modular approach to understand how each
region of the HIV-1 envelope protein, such as the V3 loop, CD4 binding site, and gp120-gp41
interaction site, might exert an impact on envelope-coreceptor interaction and coreceptor
specificity, through direct or indirectly mechanisms. Despite of recent progress in understanding
the HIV-1 envelope trimer structure at different states of activation, it has been a challenge to
understand the multimeric, dynamic interaction process of HIV entry using structural methods
such as crystallography (3, 4). In-depth association studies using multiple patients on NGS
platforms, biochemical and biophysical analysis of single clones, as well as site-directed
mutagenesis studies that focus on a fine-resolution understanding of effects of single residues,
are needed to piece together the jigsaw puzzle of the big picture of HIV envelope-coreceptor
interaction. The information gained through thorough structure-function analysis proposed above
147

would hopefully contribute to a comprehensive model of protein interaction energy landscape,
with which the impact of mutations and pharmaceutical interventions to enhance or disrupt the
said interaction could be accurately simulated, thus extending our knowledge of the basic
biology of protein-protein interaction, and guiding the development of future therapeutic agents.
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4.3 Future work
4.3.1 Phenotypic characterization of envelope-coreceptor interaction using biochemical,
biophysical, and biological assays
In order to further our understanding of envelope sequence signature and its relationship
with regard to tropism, more patient samples should be analyzed using a combination of the
single clone and NGS approach. For the single clone analysis, additional work should be
performed to fully characterize specific envelope clones that exhibit interesting coreceptor usage
properties. Biochemical assays to analyze glycosylation levels of patient-derived clones might be
useful in understanding how glycosylation of the envelope influences coreceptor binding and
specificity superimposed on top of other observed mutations (5, 6). Biophysical approaches to
accurately determine the binding affinities between envelope clones and CCR5 or CXCR4 can
be performed using atomic force microscopy, as a previous study showed that HIV-1 envelope
binds less strongly to CXCR4, and mutations in gp41 region that affect the formation of six-helix
bundle might turn out to be a rate-limiting factor while the envelope is in weak association with
CXCR4 (7). Biological assays including inhibitor IC50 analysis on the single clones or the
quasispecies libraries might show a difference in how the VCV sensitive versus resistant
envelopes respond to varying concentrations of coreceptor antagonists, thus probing the
mechanism of resistance (8-10).
In addition, infection of chimeric coreceptor expressing U87-CD4 cell lines (NIBSC, UK)
using patient-derived single clones and functional libraries would help dissect the interaction
between envelope and specific regions of CCR5 and CXCR4. The three chimeric cell lines FC-1,
FC-4b, and FC-6 were constructed so each one contains specific region of CXCR4 on a CCR5
backbone (Figure 4.4.1). Previous studies categorized R5-tropic lab adapted and patient derived
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single clones on these cell line into narrow-R5 and broad-R5, and showed that broad-R5 variants
are more likely to undergo coreceptor shift to obtain the ability to use CXCR4 for entry (11-14).
With these cell lines, we hope to define a sequence signature on HIV-1 envelope that correlates
with its ability to utilize a particular chimeric cell line, thus deducing the key interaction domains
on CXCR4 that is required for entry.
The three chimeric cell lines were quality-controlled using PCR, sequencing and flow
cytometry. PCR using primers binding to the CCR5 amino-terminus and CXCR4 carboxylterminus generated correct-sized products from the genomic DNA of FC-1, FC-4b, and FC-6,
confirming the presence of chimeric coreceptor transgene in the genome. Sequencing of these
PCR products confirmed the correct identity of these transgenes in the three cell lines,
respectively. Flow cytometry of surface stained FC-1, FC-4b, and FC-6 cells using antibodies
against CD4 (clone Q4120), CCR5 (clone 12G5) and CXCR4 (clone 2D7) showed a high level
of cell surface expression of CD4, CCR5, and CXCR4, making these cell lines ideal for
infectivity assays (data not shown).
Infection of chimeric cell lines was performed using single clones as well as functional
libraries from Sample 1.2 passaged on X4. Interestingly, the single control clone from Sample
1.2 that was previously determined to be dual-tropic with a preference for CXCR4 was able to
infect FC-4b at a comparable efficiency as the CXCR4-expressing cell line, and to a lesser extent
FC-6, but was completely non-infectious on the FC-1 cell line (Figure 4.4.2). Similarly, the
functional library from Sample 1.2 passaged on the CXC4-expressing cell line could infect FC4b, and to a lesser extent, FC-6, but was unable to infect FC-1. This observation suggests that a
combination of the CXCR4 N-terminus and CCR5 extracellular loops were counterproductive
for dual-tropic viral entry. A single, dual-tropic envelope clone might utilize different
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determinants to interact with CCR5 or CXCR4, and a “mixed-and-match” scenario for the twosite interaction model did not allow viral entry. Additionally, it showed the importance of CCR5
N-terminus for an envelope-R5 interaction, which is supported by previous studies (15, 16).
Upon receiving the NGS dataset of FC-4b and FC-6 functional libraries of Sample 1.2 passaged
on X4-expressing cells, analysis will be performed to understand the quasispecies that can utilize
the two specific chimeric coreceptors, and hopefully reveal the sequence signature that allows
them to interact with one chimeric cell line but not the other. More single clones from Subject 1
and 2 should also be tested to differentiate narrow versus broad R5 clones, as well as narrow
versus broad dual/X4 clones.

4.3.2 Genotypic analysis of envelope-coreceptor interaction using bioinformatics tools
To better understand the quasispecies evolutionary process, more bioinformatics tools
could be used to study the relationship between different envelope single clones or variants, and
make correlation between evolution and function. In particular, dN/dS analysis could be
performed using variants from before and after treatment, alone and combined, to reveal the
similarity between each pair and position of every variant on a maximum likelihood
phylogenetic tree. The input for this above-mentioned dN/dS study could be full-length gp160
envelope sequence from single clone sequencing or Pacific Biosciences Read of Insert, or
sequences of specific envelope regions, such as gp120, gp41, or sub-regions such as each
individual conserved regions C1 through C5, and variable regions V1 through V5, or even using
a sliding window format to determine the evolutionary selection on every continuous stretch of
the envelope gene. A dN/dS value greater than 1 could indicate significant positive selection
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pressure on the specific input region, due to a relatively weak power of this analysis on closely
related species.
Another bioinformatics analysis that should be done with the existing dataset is a linkage
analysis between different single nucleotide polymorphism (SNP) loci along the full-length
gp160 coding sequence. Thanks to the long read length by Pacific Biosciences sequencing
platform, it is now possible to detect positions that co-vary in X4-using or R5-using variants. A
Viral Epidemiology Signature Pattern Analysis (VESPA) tool on HIV database website can be
used to examine residue frequencies in the two different groups of variants, thus identifying
sequence signature patterns associated with coreceptor specificity across the length of the
envelope.
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4.4 Conclusions
This study utilized a panel of patient-derived envelope amplicon samples to interrogate
the evolutionary process of coreceptor shift in vivo under the specific selection pressure of a
CCR5 antagonist therapy. Four samples from two subjects were examined in-depth to reveal
drastic population-level shift of quasispecies from before to after CCR5 antagonist treatment.
SNP analysis highlighted regions of interest on the envelope protein that strongly associate with
coreceptor specificity, which includes residues near and on the V3 loop, at the CD4 binding site,
and at the interaction surface between gp120 and gp41 within the same heterodimer and among
neighboring heterodimers in an envelope trimeric spike. Future work should continue to perform
phenotypic and genotypic analysis on more patient-derived samples using single clone and NGS
approach on CCR5, CXCR4, and chimeric coreceptor expressing cell lines to (1) understand if
the findings on two patients are broadly applicable to other patients; (2) explore structurefunction relationship in vitro with biochemical, biophysical, and biological methods; and (3)
analyze the evolutionary relationship between quasispecies using bioinformatics approaches. The
enhanced understanding of HIV-1 envelope interaction with host cell coreceptor CXCR4 may
have implications in basic biology of protein-protein interaction, as well as important clinical
implications in the diagnosis, monitoring, and treatment options for HIV/AIDS.
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4.5 Figures
Figure 4.5.1 Schematic diagram of CCR5, CXCR4, and the chimeric coreceptors FC-1,
FC-4b, and FC-6.

The diagram is color coded with parental constructs CXCR4 (left) in black, and CCR5 (right) in
pink. Chimeric coreceptor constructs FC-1, FC-4b and FC-6 are colored accordingly, with
regions from CXCR4 colored black, and regions from CCR5 colored pink.
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Figure 4.5.2

Luciferase based infectivity assay on U87.CD4 chimeric coreceptor cell lines

using Sample 1.2 single control clone.

U87.CD4 is the negative control parental cell line and does not express significant levels of
CCR5 or CXCR4. R5: U87.CD4.CCR5 cell line; X4: U87.CD4.CXCR4 cell line. A grey dotted
line at RLU = 917 indicts the cut-off value below which is considered negative background.
RLU: relative light unit.
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